

On the *N*-arylation of acetamide using 2-, 3- and 1'-substituted iodoferrocenes

Lingaswamy Kadari,^{a,b} William Erb,^{a*} Yury S. Halauko,^{c*} Oleg A. Ivashkevich,^d Vadim E. Matulis,^d Dmitry Lyakhov,^e Thierry Roisnel,^a Palakodety Radha Krishna^{b*} and Florence Mongin^a

- [a] Dr. L. Kadari, Dr. W. Erb, Dr. T. Roisnel, Prof. F. Mongin
Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, F-35000 Rennes, France
E-mail: william.erb@univ-rennes1.fr
- [b] Dr. L. Kadari, Dr. P. Radha Krishna
Organic Synthesis and Process Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.
E-mail: prkgenius@iict.res.in
- [c] Dr. Y. S. Halauko,
UNESCO Chair of Belarusian State University, 14 Leningradskaya Str., Minsk 220030, Belarus.
E-mail: hys@tut.by
- [d] Prof. O. A. Ivashkevich, Dr. V. E. Matulis
Research Institute for Physico-Chemical Problems of Belarusian State University, 14 Leningradskaya Str., Minsk 220030, Belarus.
- [e] Dr. D. Lyakhov
Computer, Electrical and Mathematical Science and Engineering Division, 4700 King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia.

Abstract: Various 2-, 3- and 1'-substituted iodoferrocenes were reacted with acetamide in the presence of copper(I) iodide (1 equiv), *N,N*-dimethylethylenediamine (1 equiv), tripotassium phosphate (2 equiv) in dioxane at 90 °C for 14 h, and allowed a large range of original 1,2-, 1,3- and 1,1'-disubstituted ferrocenes to be obtained. The results were compared as a function of the substituent and its position on the ring. DFT calculations revealed higher activation barrier for the oxidative addition in the ferrocene series when compared with classical planar aromatics. Structure–property relationships were applied to rationalize the reactivity of the different iodoferrocenes.

Introduction

The *N*-arylation of amides, also known as the Goldberg condensation,^[1] and above all its copper-catalyzed variants that don't require harsh reaction conditions,^[2] have demonstrated their value for the multistep synthesis of bioactive compounds such as antagonists of VLA-4 (very late antigen-4) protein,^[3] inhibitors of PDE5 (phosphodiesterase-5) enzyme,^[4] antiplasmodials,^[5] inhibitors of tankyrase protein,^[6] inhibitors of Xa factor,^[7] inhibitors of trypanosome proliferation^[8] and inhibitors of EGFR (epidermal growth factor receptor) tyrosine protein kinase.^[9]

This success results from the discovery of efficient catalytic systems able to operate under smooth conditions, such as the one developed by Buchwald and co-workers consisting of a combination of an air stable copper(I) salt, an aliphatic chelating 1,2-diamine and a base to *N*-arylate amides by halides (I > Br > Cl).^[10] As regards mechanism, it is admitted that the reaction between the aryl halide and a 1,2-diamine ligated copper(I) amidate giving a copper(III) species is the rate determining step that precedes reductive elimination.^[11] As a consequence, the reaction outcome is a function of both the aryl halide and the amide as the ability of the latter to stabilize an aryl-Cu(III)-amido species would have a significant impact on the course of the reaction.^[12] Steric hindrance and poor nucleophilicity of the amidate are the reasons generally invoked to explain why the scope of copper-catalyzed *N*-arylation of amides is not larger.^[13]

With regard to the aryl halide, it has been demonstrated that a methyl group present at the *ortho* position of iodobenzene hampers to some extent its reaction with 2-pyrrolidinone.^[11c] Besides, it has been shown in 2009 that iodobenzenes bearing electron-deficient groups at their 4 position facilitate the reaction (CN > COMe > Cl > H) while others bearing electron-donating groups jeopardize (OMe < Me < H) the aryl iodide activation.^[11b] A similar conclusion was made by reacting both benzamide and 2-pyrrolidinone with iodobenzenes bearing either electron-withdrawing 4-nitro group or electron-donating 4-methyl group.^[12c] However, from planar aryl iodides, the reaction generally tolerates a large range of substituents as shown in the benzene series (2- and 4-OMe, 2- and 4-NMe₂, 4-NH₂, 2- and 3-Me, 2-*i*Pr, 4-SMe, 3-CH₂OH, 3-CH₂NH₂, 3-CN, 3-COMe, 4-Cl, 4-CH₂CN, 4-CONHR, 4-CO₂R and 2-NO₂) and by the use of thiophene and azine/diazine halides.^[10]

Notably due to their three-dimensional structure and ability to undergo facile one-electron oxidation, ferrocenes are quite different from benzenes. While ferrocene and its derivatives have found numerous applications,^[14] they exhibit their own behavior in several reactions.^[15] Consequently, as copper-catalyzed *N*-arylation of carboxamides using iodobenzenes is currently well-described, the corresponding reaction in the ferrocene series remains in its infancy. Indeed, whereas iodoferrocene can react with amides by recourse to copper-based systems,^[16] the involvement of 2-substituted derivatives in such couplings is far less obvious due to competitive deiodination.^[16c] While continuing our work dedicated to the synthesis of ferrocene amides,^[17] we recently reported the successful *N*-arylation using iodoferrocene of a large range of carboxamides.^[18]


In the continuation of our efforts to develop synthetic methods in the ferrocene series and to understand their specific behavior,^[17,19] we were eager to study the effect of an additional substituent at the 2-, 3- or 1'-position of iodoferrocene on the amide *N*-arylation. To this goal, 35 substituted iodoferrocenes were engaged in the copper-mediated *N*-arylation reaction, leading to 28 original *N*-ferrocenyl acetamides, isolated in moderate to good yields which were tentatively linked to the structural and electronic features of the iodo partners.

Results and Discussion

Synthesis of the *N*-ferrocenyl acetamides

From the literature on the *N*-arylation of amides using iodoferrrocene (**1a**), two catalytic systems were selected for this study: (i) the one reported in 2007 by Bolm and co-workers using copper(I) iodide and potassium *tert*-butoxide in dimethylsulfoxide (DMSO) at 90 °C,^[16c] and (ii) the other we recently reported based on the use of copper(I) iodide, *N,N'*-dimethylethylenediamine (DMEDA) and tripotassium phosphate in dioxane at 90 °C.^[18] Early evaluation of Bolm's system^[16c] starting from 2-substituted iodoferrrocenes bearing CH₂OMe, CO₂Me or CONiPr₂ moieties only afforded the corresponding products in low yields (19, 4.5 and 6.5%, respectively) partly due to competitive deiodination (16, 37 and 54.5% yield, respectively). As the other conditions were able to deliver *N*-ferrocenylacetamide (**2a**) in 82% yield from iodoferrrocene (**1a**) (Scheme 1), this protocol was selected to study the substituent impact on the course of the copper-mediated acetamidation of iodoferrrocenes (Table 1).


Thus, the coupling reactions between acetamide and the 35 synthesized 2-, 3- or 1'-substituted iodoferrrocenes **1b-m**, **3b-m** and **5b-l** were all performed in the presence of copper(I) iodide (1 equiv), *N,N'*-dimethylethylenediamine (DMEDA; 1 equiv) and tripotassium phosphate (2 equiv) in dioxane at 90 °C for 14 h.



Scheme 1. *N*-arylation of acetamide with iodoferrrocene.

Most of the expected 1,2-, 1,3- and 1,1'-disubstituted ferrocenes **2b-m**, **4b-m** and **6b-l** were obtained, albeit in yields depending on both the substituent present on the initial iodoferrrocene and its position. In particular, the products **2d**, **2i** and **2j**, already obtained respectively in 19, 4.5 and 6.5% yields from the iodoferrrocenes **1d**, **1i** and **1j** by using Bolm's procedure, were isolated in 61, 51 and 15% yields by using our protocol (entries 7, 22 and 25). It is interesting to note that, besides the starting substituted iodoferrrocene, the corresponding deiodoferrrocene was also present at the end of most of these reactions.

Table 1. *N*-arylation of acetamide with 2-, 3- and 1'-substituted iodoferrrocenes.



Entry	Iodoferrrocene, R	Product, Yield (%) ^[a]
1	1b , 2-Me	2b , 61 ^[b]
2	3b , 3-Me ^[19i]	4b , 65 ^[c] (21; 7) ^[b]
3	5b , 1'-Me ^[19i]	6b , 80 ^[b]
7	1d , 2-CH ₂ OMe	2d , 61 ^[b]
8	3d , 3-CH ₂ OMe ^[19i]	4d , 51 ^[d] (34; 5) ^[b]
9	5d , 1'-CH ₂ OMe ^[19i]	6d , 67 ^[b,c]
13	1f , 2-CHO ^[20]	2f , 12 ^[c] (-; 55) ^[b]
14	3f , 3-CHO ^[19i]	4f , 12 (49; 15) ^[b]
15	5f , 1'-CHO ^[19i]	6f , 30 ^[b]
19	1h , 2-CN ^[20]	2h , 24 ^[b]
20	3h , 3-CN ^[19i]	4h , 30 ^[c] (-; 70) ^[b]
21	5h , 1'-CN ^[19i]	6h , 40 ^[b]
22	1i , 2-CO ₂ Me ^[20]	2i , 51 ^[b]
23	3i , 3-CO ₂ Me ^[19i]	4i , 37 (10; 53) ^[b]
24	5i , 1'-CO ₂ Me ^[19i]	6i , 54 ^[b]
28	1k , 2-NMe ₂ ^[21]	2k , 0 ^[b]
29	3k , 3-NMe ₂ ^[19i]	4k , 28 (-; 26) ^[b]
30	5k , 1'-NMe ₂ ^[19i]	6k , 0 ^[f]
34	1m , 2-F ^[19c]	2m , 34 ^[d] (19; 25) ^[b]
35	3m , 3-F ^[19g]	4m , 57 ^[c] (5; 20) ^[b]

Entry	Iodoferrrocene, R	Product, Yield (%) ^[a]
4	1c , 2-CH ₂ NiPr ₂	2c , 0 ^[b]
5	3c , 3-CH ₂ NiPr ₂ ^[19a]	4c , 66 ^[b]
6	5c , 1'-CH ₂ NiPr ₂ ^[19i]	6c , 52 ^[b]
10	1e , 2-CH ₂ OH	2e , 0 ^[b]
11	3e , 3-CH ₂ OH ^[19i]	4e , 25 (25; 17) ^[b]
12	5e , 1'-CH ₂ OH ^[19i]	6e , 18 ^[b]
16	1g , 2-COPh ^[20]	2g , 13 ^[b]
17	3g , 3-COPh ^[19i]	4g , 19 (-; 56) ^[b]
18	5g , 1'-COPh ^[19i]	6g , 25 ^[b]
25	1j , 2-CONiPr ₂ ^[19a]	2j , 15 ^[e]
26	3j , 3-CONiPr ₂ ^[19a]	4j , 77 ^[e]
27	5j , 1'-CONiPr ₂ ^[19i]	6j , 39 ^[b]
31	1l , 2-NHCO ₂ tBu	2l , 8.5 (-; 81) ^[b]
32	3l , 3-NHCO ₂ tBu ^[19i]	4l , 17 (-; 19) ^[b]
33	5l , 1'-NHCO ₂ tBu ^[19i]	6l , 30 ^[b]

[a] After purification (see experimental part). [b] The rest was mainly recovered starting material (**1**, **3** or **5**) and the corresponding deiodinated ferrocene; for some reactions, the respective yields are given in brackets. [c] Average yield over two experiments. [d] Average yield over three experiments. [e] The rest was mainly the deiodinated ferrocene. [f] Decomposition under the conditions used for the reaction.

Oxidative addition as rate determining step


It is in general admitted in the benzene series that the rate determining step of a copper-catalyzed amidation is the reaction between the aryl halide and the 1,2-diamine ligated copper(I) amidate, reaction that gives a copper(III) species.^[11c,22] Thus, we first tried to analyze our experimental results by using the data reported on oxidative additions.

The ease by which oxidative addition of aryl halides by palladium(0) species takes place inversely depends on the energy to distort the carbon-halogen bond to the transition state geometry which is related to the C-X bond dissociation energy.^[23] Furthermore, the oxidative addition might also depend on the arene LUMO, with favored frontier molecular orbitals interactions in the presence of electron-withdrawing substituents.^[23-24]

In palladium-catalyzed coupling reactions for which oxidative addition is rate determining, one simplified approach to predict the reactivity of substrates bearing multiple identical halogens is based on NMR chemical shifts, the preferred reaction site being in general the most electron-deficient carbon.^[25] Thus, the ¹H chemical shifts of the corresponding dehalogenated arenes,^[26] and the ¹³C chemical shifts of the halogenated arenes,^[27] were proposed as a way to provide insight into the electrophilicities.

Because we benefited from the complete NMR data of all the 2-, 3- and 1'-iodoferrocenes **1b-m**, **3b-m** and **5b-l**, the experimental results were compared in the light of the NMR chemical shifts of the carbons bearing iodine, δ (C-I). In order to more easily analyze the results, the values relative to iodoferrrocene (**1a**) were calculated and given in brackets (Table 2).

Table 2. ¹³C NMR chemical shift of the C-I in CDCl₃ for the different iodoferrrocenes involved in the reaction with acetamide.



Entry	Substrate	R	δ (C-I) [$\Delta\delta$] ^[a]		
			1	3	5
1	a	H	39.9		
2	b	Me	46.6 [+6.7]	39.7 [-0.2]	40.9 [+1.0]
3	c	CH ₂ NiPr ₂	45.4 [+5.5]	39.8 [-0.1]	41.0 [+1.1]
4	d	CH ₂ OMe	45.0 [+5.1]	39.8 [-0.1]	40.1 [+0.2]
5	e	CH ₂ OH	43.9 [+4.0]	39.7 [-0.2]	40.1 [+0.2]
6	f	CHO	42.0 [+2.1]	41.3 [+1.4]	39.4 [-0.5]
7	g	COPh	41.1 [+1.2]	41.3 [+1.4]	40.0 [+0.1]
8	h	CN	41.6 [+1.7]	38.6 [-1.3]	39.8 [-0.1]
9	i	CO ₂ Me	39.8 [-0.1]	40.0 [+0.1]	40.4 [+0.5]
10	j	CONiPr ₂	40.5 [+0.6]	39.6 [-0.3]	40.1 [+0.2]
11	k	NMe ₂	38.7 [-1.2]	39.7 [-0.2]	40.6 [+0.7]
12	l	NHCO ₂ tBu	37.7 [-2.2]	37.6 [-2.3]	42.6 [+2.7]
13	m	F	28.9 [-11.0]	33.6 [-6.3]	-

[a] $\Delta\delta = \delta$ (C-I) of the disubstituted ferrocene - δ (C-I) of iodoferrrocene.

On the basis of their ¹³C NMR spectra, Me, CH₂NiPr₂, CH₂OMe and CH₂OH should exhibit similar electronic effects. Indeed, they make the δ (C-I) values increase significantly on their adjacent site (substrates **1b-e**; Table 2, entries 2-5). As a consequence, oxidative addition should be favored by the presence of these groups at C2. The results do not follow our predictions; in the case of Me and CH₂OMe, still good yields of 61% were recorded (entries 1 and 7), but no reaction took place with CH₂NiPr₂ and CH₂OH (entries 4 and 10). If steric hindrance can be invoked to rationalize slightly lower yields (Me and CH₂OMe), additional competitive interaction could also be considered in the case of CH₂NiPr₂ and CH₂OH.

Indeed, when our reference coupling between iodoferrrocene (**1a**) and acetamide (Scheme 1) was attempted in the presence of (diisopropylaminomethyl)ferrocene (1 equiv) or ferrocenemethanol (1 equiv) as additive, the yield of the coupled product **2a** dropped to 35% and 47%, respectively, while the additive was almost recovered (74% and 81%, respectively).

While the presence of Me, CH₂NiPr₂ and CH₂OMe at C3 and C1' has only a small impact on the coupling yields (Table 1, entries 2, 3, 5, 6, 8 and 9), low yields were noticed in the presence of CH₂OH (entries 11 and 12).

According to the chemical shifts, all substituents of Table 2 from entry 6 to 12 should display a similar behavior. However, among CHO, COPh, CN, CO₂Me, CONiPr₂, NMe₂ and NHCO₂tBu, the ester function is the only tolerated when located at C2 (Table 1, entry 22). When present at C3, the carboxamide and, to a lesser extent, the ester are compatible (entries 26 and 23); this order is reversed when these groups are moved to the C1' position (entries 24 and 27).

These results are difficult to rationalize due to the low stability of aldehyde- and ketone-containing (Table 1, entries 13-18) and amine-based ferrocenes (entries 28-33). Furthermore, steric hindrance can be invoked in the case of CONiPr₂ at C2 (entry 25) while coordination can be advanced for CN (entries 19-21). Indeed, performing our reference reaction between **1a** and

acetamide in the presence of ferrocenecarbonitrile (1 equiv) led to **2a** in a moderate 38% yield (41% of **1a** recovered; full nitrile recovery).

F has a strong ability to make the δ (C-I) values decrease on the adjacent site and, to a lesser extent, at the remote 3-position (Table 2, entry 13). Consequently, the oxidative addition should be more difficult at C2 and, to a lesser extent, at C3, as observed experimentally (products **2m** and **4m** respectively isolated in 34 and 57% yield; entries 34 and 35).

All these results show that the predictive approach based on the δ (C-I) values can be hardly applied to the ferrocene series, while it works rather well for planar aromatic and heteroaromatic halides.

In order to understand the underlying reasons, we tried quantitative structure-properties relationships (QSPR) approach and electronic structure methods. As in the Handy's NMR approach,^[26] we considered the deiodinated substrates. Furthermore, we excluded the substrates **e**, **j**, **k**, **l**, for which yield should be more influenced by steric hindrance or specific interactions than electronic effects. A range of conceptual density functional theory (CDFT) descriptors has been calculated (Table S1; see Supporting Information). These could be classified into local and global properties.

Regarding the quite high temperature and reaction time, we assumed yield to be a solid measure of reactivity. When trying to describe yield (%) on a single-variable basis, one could obtain as best model:

$$\%y = 126 - 118\omega \quad (N = 23, r^2 = 0.75).$$

Experimental and predicted yields were compared graphically in Figure S1 (see Supporting Information). This result could be interpreted as follows: yield decreases with increasing electrophilicity index (ω), meaning that electron-donating groups in general favor the process.

In order to have a better understanding of the reactivity, we averaged yield over positions of parent ferrocenes (Table S2; see Supporting Information) and repeated regression analysis. A similar model equation was obtained:

$$\%y = 122 - 114\omega \quad (N = 9, r^2 = 0.70).$$

Furthermore, it is obvious that steric factor could be pronounced for substituents at C2 and C1', so we decided to probe yield at C3 only as 'most pure' with respect to electronic influence. In addition to similar

$$\%y = 135 - 132\omega \quad (N = 9, r^2 = 0.82),$$

we obtained an even better model:

$$\%y = -1484 - 6500q_{\text{NBO}} \quad (N = 9, r^2 = 0.88),$$

which means more negative natural bond orbital atomic charge (q_{NBO}) on carbon favors the corresponding *N*-ferrocenyl acetamide's yield.

Interestingly, no prominent correlation between δ (C-I) values and descriptors on a single-variable basis exists. Therefore, it is better to rationalize the reactivity of the different iodoferrocenes in view of their global molecular properties rather than to local carbon descriptors.

Comparison with the corresponding benzenes

When compared with the literature about similar transformations in the benzene series, iodoferrocenes clearly appear as less reactive. In the event that oxidative addition is the rate determining step, it is known from the literature that its ease is

related to both the carbon-halogen bond strength and the electronic environment.^[23-24] With respective values of 94.3^[28] and 39.9 ppm, the NMR δ (C-I) of iodobenzene and iodoferrocene (**1a**) are in favor of a less easier oxidative addition for the latter.


The free energy of activation for the oxidative addition of iodobenzene (**PhI**), iodoferrocene (**1a**) and the 3-substituted iodoferrocenes **3b**, **3f** and **3h** to the [(dmeda)Cu(pyrr)] complex (pyrr = 2-pyrrolidinone) has been computed, and the results are summarized in Table 3. The computed energy barrier for the reaction of [(dmeda)Cu(pyrr)] complex with iodobenzene (**PhI**; 24.7 kcal/mol, Table 3) is in a good agreement with the value of 25 kcal/mol calculated by Tye and co-workers for the reaction in toluene.^[11c,29] The predicted energy barrier for iodoferrocene (**1a**) is much higher (28.5 kcal/mol, Table 3), and agrees well with the lower reactivity of iodoferrocenes when compared with the corresponding iodobenzenes. Our calculations show that the energy barriers for reactions of [(dmeda)Cu(pyrr)] complex with the considered 3-substituted iodoferrocenes **3b**, **3f** and **3h** are close, but slightly higher than for the unsubstituted iodoferrocene. In addition to coordination and stability issues, it is thus not surprising that low reactivities were in general noticed from our substituted iodoferrocenes when compared with the corresponding benzenes.

Table 3. Calculated free energy of activation (ΔG^\ddagger) for the reactions of [(dmeda)Cu(pyrr)] complex with iodobenzene (**PhI**), iodoferrocene (**1a**) and the 3-substituted iodoferrocenes **3b**, **3f** and **3h**.

Substrate	ΔG^\ddagger (kcal/mol)
iodobenzene	24.7
1a	28.5
3b , 3-Me	30.1
3f , 3-CHO	29.1
3h , 3-CN	28.9

Houk and co-workers considered selectivity in palladium-catalyzed cross-couplings of halogenated heterocycles in terms of molecular orbital control.^[23-24] Generally, effective interactions require orbitals of similar energy and correspondent symmetry. In addition to interactions, responsible for the bond-forming/breaking processes, other stabilizing frontier molecular orbitals (FMO) interactions are possible. But our calculations predict principal FMO differences between haloarenes, haloheteroaromatics, and haloferrocenes (Scheme 2).

HOMO and HOMO-1 of iodoferrocene (**1a**) could be described as mainly *d* orbitals of iron.^[30] For iodobenzene (**PhI**) and 2-iodopyridine (**2-IPy**), HOMOs are antibonding π orbitals. LUMO and LUMO+1 of **2-IPy** are antibonding π orbital and σ^* (C-I), correspondingly; when coming to iodobenzene and **1a**, the LUMO/LUMO+1 order is swapped (Scheme 2a). Thus, the oxidative addition transition state for iodoferrocenes can hardly be stabilized by (*d*- π^*) back-donation mentioned by Houk (for a schematic representation, see Scheme 2b).^[24] This in turn can partially describe why electron-deficient groups do not increase the amidation yield.



Scheme 2. (a) FMO profile of the selected species; (b) schematic representation of the allowed interactions between 2-iodopyridine (**2-IPy**) and Pd(0)^[24] vs those of iodoferrocene (**1a**) and Cu(I).

Table 4. Carbon Mulliken charges calculated for the deiodinated ferrocenes corresponding to some of the different iodoferrocenes involved in the reaction with acetamide.

Substrate	R	Mulliken [Δ Mulliken] ^[a]			
		At C2	At C3	At C1'	
	a	H	-0.134		
	b	Me	-0.152 [-0.018]	-0.133 [+0.001]	-0.138 [-0.004]
	c	CH ₂ NiPr ₂	-0.135/-0.139 [-0.003]	-0.131/-0.135 [+0.001]	-0.138 [-0.004]
	d	CH ₂ OMe	-0.137/-0.155 [-0.012]	-0.139/-0.131 [-0.001]	-0.132 [+0.002]
	f	CHO	-0.148/-0.163 [-0.0215]	-0.121/-0.128 [+0.0095]	-0.134 [0]
	g	COPh	-0.139/-0.172 [-0.0215]	-0.124/-0.131 [+0.0065]	-0.134 [0]
	h	CN	-0.121 [+0.013]	-0.127 [+0.007]	-0.133 [+0.001]
	i	CO ₂ Me	-0.140/-0.141 [-0.0065]	-0.128/-0.130 [+0.005]	-0.135 [-0.001]
	m	F	-0.190 [-0.056]	-0.135 [-0.001]	-0.139 [-0.005]

[a] Δ Mulliken = Mulliken charge of the substituted ferrocene – Mulliken charge of bare ferrocene.

Table 5. Carbon Mulliken charges calculated for the corresponding deiodinated benzenes.

Substrate	R	Mulliken [Δ Mulliken] ^[a]			
		At C2	At C3	At C4	
	a	H	-0.129		
	b	Me	-0.179 [-0.050]	-0.127 [+0.002]	-0.133 [-0.004]
	c	CH ₂ NiPr ₂	-0.166/-0.188 [-0.048]	-0.131/-0.128 [-0.0005]	-0.130 [-0.001]
	d	CH ₂ OMe	-0.162/-0.179 [-0.0415]	-0.133/-0.130 [-0.0025]	-0.128 [+0.001]
	f	CHO	-0.156/-0.177 [-0.0375]	-0.131/-0.132 [-0.0025]	-0.119 [+0.010]
	g	COPh	-0.151/-0.177 [-0.035]	-0.135/-0.137 [-0.0070]	-0.119 [+0.010]
	h	CN	-0.134 [-0.005]	-0.133 [-0.004]	-0.116 [+0.013]
	i	CO ₂ Me	-0.152/-0.158 [-0.026]	-0.138/-0.137 [-0.0085]	-0.117 [+0.012]
	m	F	-0.195 [-0.066]	-0.130 [-0.001]	-0.130 [-0.001]

[a] Δ Mulliken = Mulliken charge of the substituted benzene – Mulliken charge of bare benzene.

Even if oxidative addition is generally considered as the rate determining step of this copper-catalyzed amidation, we analyzed the possibility of a decisive reductive elimination step as a function of the substituent and its position. Indeed, although it was in palladium-catalyzed amination, Hartwig and co-workers showed that reductive elimination with C-N bond formation was influencing for series of five-membered heteroaryl halides, with less electron-rich aryl moiety favoring the process.^[31] To this purpose, the Mulliken charges on carbons were calculated (Table 4; B3LYP calculations with a 6-31G(d) basis set). These calculations show that the introduction of substituents at C3 or C1' have a very limited impact on the electron-rich character of the ferrocenyl group. Logically, the effect is more significant when the substituent is fixed at C2. With F and, to a lesser extent, CHO, COPh, Me and CH₂OMe, the corresponding 2-substituted ferrocenyl is more electron-rich, and reductive elimination should be disfavored. This might partly (together with oxidative addition) explain the low yield observed from **1m**; however, this could

hardly explain why the yields of the couplings from **1b**, **1d** and **1g** are not at the maximal value in spite of high δ (C-I) (Table 1).

The Mulliken charges on carbons for the corresponding deiodinated benzenes were similarly calculated for comparison purpose (Table 5). As before, introducing remote substituents at C3 and C4 has a limited impact on the electron-rich character of the phenyl group; however, the same substituents fixed at C2 exert in general a stronger effect, making the 2-substituted phenyls more electron-rich, and thus more able to disfavor reductive elimination. As the substituent effect is even less pronounced in the ferrocene series, reductive elimination as determining step is less likely.

This analysis of the reaction yields as a function of both the substituent and its position onto ferrocene shows that reaction conditions cannot be simply transposed from halogenated benzenes to the corresponding ferrocenes. This access to *N*-ferrocenyl amides highly depends on the nature and, to a lesser extent, on the position of the substituent (e.g. amino groups) onto

the iodinated partner, and this behavior strongly differs from the benzene series. Indeed, similar couplings between amides and iodobenzenes bearing for example 3-CH₂OH, 3-COMe, 3-CN, 4-CONHR and 4-CO₂R can be carried out in good yields.^[10] However, when more elaborated aryl iodides^[3,6-7,9,31] or iodinated heteroaromatics^[8,32] are similarly reacted with amides, lower yields are more commonly obtained.


Evidence toward unlikely radical pathway

In the frame of studies dedicated to the mechanism of the copper-catalyzed *N*-arylation of amides, authors tried to use radical clocks such as 1-allyloxy-2-iodobenzene as substrate.^[11c,22a] However, they never observed any traces of cyclized product that could evidence the involvement of radical species. For this reason, they discarded a radical pathway in spite of observed protodeiodation (which is often a side reaction in Ullmann couplings).^[22a] Protodeiodation side reactions were noticed previously by Cohen^[33] and Hartwig^[11c] in similar reactions, and even by reacting generated aryl-Cu(III) complexes.^[22b] We also observed protodeiodation in our experiments, for example in the case of iodoferrocenes substituted by electron-withdrawing groups such as CHO, CPh, CN and CO₂Me, but also with NHCO₂tBu. By coupling acetamide with iodoferrocene (**1a**) as in Scheme 1, but in the presence of 2,2,6,6-tetramethyl-1-piperidyloxy (TEMPO; 1 equiv) as additive in order to intercept a putative radical, the expected product **2a** was formed in a moderate 33% yield. While a careful purification of the crude did not yield any TEMPO derivative, bare ferrocene was isolated in 59% yield without recovery of starting material **1a**, explaining why the reaction stopped. Interestingly, by carrying out our reference reaction (Scheme 1) without acetamide, ferrocene was only formed in 2% yield while 85% of the starting iodoferrocene (**1a**) was recovered; this result shows that the amide plays a role in this protodeiodation. Similarly, without acetamide but in the presence of TEMPO (1 equiv), no ferrocene was obtained and **1a** was recovered in 88% yield, indicating that the amide is required in this protodeiodation. Finally, simply heating **1a** with TEMPO in dioxane at 90 °C for 14 h only provided recovered **1a**, isolated in 92% yield. Therefore, all these results tend to indicate that protodeiodation takes place from the arylcopper(III) intermediate, formed by reversible oxidative addition of the C-I bond to copper(I)^[22b] through protonation by the amide. The reason why TEMPO favors protodeiodation might be a participation in the arylcopper(III) intermediate, disfavoring reductive elimination.

In a last attempt to intercept a putative ferrocenyl radical, we considered a radical cyclization reaction using indole as radical acceptor.^[34] To that end, the 2-substituted iodoferrocene **1n** was treated with tributyltin hydride in the presence of azobisisobutyronitrile (AIBN) in toluene at 115 °C. However, after 36 h under these conditions, only traces of a cyclized product were detected while 59% of the starting **1n** were recovered. This suggests that the ferrocenyl radical could not be easily formed, as already proposed.^[35]

Finally, amidation of **1n** by 2-pyrrolidinone (which is an efficient amide partner for such couplings)^[2] gave the expected derivative **2n**, isolated in 11% yield, and 80% of recovered **1n** (Scheme 3). This low yield led us to attempt our reference coupling reaction (Scheme 1) between iodoferrocene (**1a**) and acetamide in the presence of *N*-methylindole (1 equiv) to see if this electron-rich moiety can impact the course of the reaction. As suspected, the coupling product **2a** was only isolated in a moderate 28% yield

under these conditions while 52% of starting **1a** was recovered, indicating that *N*-methylindole can jeopardize the result of the coupling reaction. Note that deiodination was not observed at all in both reactions.



Scheme 3. Reaction from **1n**.




Figure 1. Hydrogen bonds network observed at the solid state for compounds **2b** (top) and **6b** (bottom). Thermal ellipsoids shown at the 30% probability level. Cp-Cp planes angles (3.4(0.3) and 0.6(0.3) °) and (0.4(0.3) and 0.6(0.3) °) for **2b** and **6b**, respectively.

Specific solid-state structures of the ferrocene amides

In the course of this study, crystals suitable for X-ray diffraction analysis were obtained for some of the prepared acetamidoferrocene derivatives and revealed interesting differences between isomers at the solid state. Concerning the methyl-substituted compounds **2b** (Figure 1, top) and **6b** (Figure 1, bottom), while two molecules were found in the asymmetric unit of both compounds, the angles between the acetamide and the Cp ring were found different. Indeed, moving the methyl group from the 1'-position (angles of 17.0(0.2) and 24.1(0.2) ° for compound **6b**) forces the acetamide moiety to rotate (angles of 55.5(0.2) and 59.2(0.1) ° for compound **2b**) probably for steric reasons. Different hydrogen bonds networks were also identified as only one string of hydrogen bonds links the acetamide groups in compound **2b** while two parallel strings of hydrogen bonds going in the same direction were observed in compound **6b**.

Similar differences were also observed for the solid-state structures of the 2- and 3-substituted acetamidoferrocenes **2i** and **4i**, respectively. In the later, the acetamide is bent upward, as usually observed (21.9(0.2) and 24.5(0.2) ° angles for the two molecules found in the asymmetric unit), and engaged in a hydrogen bonds network which links the acetamide and the ester moieties with an additional water molecule which co-crystallized (Figure 2).




Figure 2. Hydrogen bonds network observed at the solid state for compound **4i**. Thermal ellipsoids shown at the 30% probability level. Cp-Cp planes angles 2.3(0.3) and 3.6(0.3) °.




Figure 3. Hydrogen bonds observed at the solid state for compounds **2i** (top) and **6j** (bottom). Thermal ellipsoids shown at the 30% probability level. Cp-Cp planes angles 0.5(0.2) and 4.0(0.2) ° for **2i** and **6j**, respectively.

On the contrary, due to the proximity between the two functional groups in compound **2i**, an intramolecular hydrogen bond between the ester and the acetamide forces the later to be close to coplanarity with the Cp ring (8.3(0.2) ° angle; Figure 3, top). Similarly, an intramolecular hydrogen bond between the acetamide and the *N,N*-diisopropylcarboxamide moiety of

compound **6j** was observed at the solid state (Figure 3, bottom). Consequently, the C=O bonds of the two groups point downward with respectively 39.3(0.1) and 48.8(0.1) ° angles between the acetamide and *N,N*-diisopropylcarboxamide and their linked Cp ring.

However, moving one substituent from the 1'-position of compound **6j** to the 3-position with compound **4j** has a profound impact on the solid-state structure. Indeed, while the free rotating Cp cycles allow the intramolecular hydrogen bond observed in **6j**, having both substituents on the same cycle favors intermolecular hydrogen bonds as observed at the solid state (Figure 4). This results in the formation of a crystalline tetramer linked by four hydrogen bonds between the acetamide and the *N,N*-diisopropylcarboxamide. Furthermore, as compound **4j** was obtained as a racemic mixture, one can notice that two opposite molecules of the tetramer are enantiomers.




Figure 4. Hydrogen bonds observed at the solid state for compounds **4j**. Thermal ellipsoids shown at the 30% probability level.

Conclusion

In the present study, we highlighted both the reactivity (in the copper-mediated *N*-ferrocenylation of acetamide) and the structural differences that can exist between the different isomeric substituted ferrocenes. While a large range of original *N*-ferrocenyl acetamides were obtained (only 3 of them were known before over the 31 here prepared) and could be included in molecular designs, we tried to rationalize their corresponding yields in terms of electronic and structural features in order to understand the impact of the substituents and their position. Although approaches are able to predict the aryl iodide activation, we evidenced the need, in the ferrocene series, for more specific predictive tools considering (i) steric hindrance inherent to the 3-D ferrocene structure (prediction was right in the case of the small fluoro group) and (ii) possible coordination to copper of some of the tested substituents. Indeed, as iodoferrocenes are less activated substrates than iodobenzenes, their substituents play an important role upon involvement in copper-catalyzed C-N bond formation.

Experimental Section

General Considerations. All the reactions were performed under an argon atmosphere and by using anhydrous solvents in dried Schlenk tubes. Column chromatography separations were achieved on silica gel (40-63 µm). Melting points were measured on a Kofler bench. IR spectra were

taken on a Perkin-Elmer Spectrum 100 spectrometer. ^1H and ^{13}C Nuclear Magnetic Resonance (NMR) spectra were recorded either (a) on a Bruker Avance III spectrometer at 300 MHz and 75 MHz, respectively, or (b) on a Bruker Avance III HD at 400 MHz and 100 MHz, respectively, or (c) on a Bruker Avance III HD at 500 MHz and 126 MHz, respectively. ^1H chemical shifts (δ) are given in ppm relative to the solvent residual peak and ^{13}C chemical shifts are relative to the central peak of the solvent signal.^[36] Mass spectra (HRMS) were recorded on a Thermo Scientific Q Exactive Orbitrap apparatus.

Dioxane was distilled over CaH_2 . Iodoferrocene (**1a**),^[17,37] 2-iodoferrocenecarboxylic acid,^[17] 1-iodo-3/1'-methylferrocenes (**3b**^[19] and **5b**^[19]), 1-(diisopropylaminomethyl)-3/1'-iodoferrocenes (**3c**^[19] and **5c**^[19]), 1-iodo-3/1'-(methoxymethyl)ferrocenes (**3d**^[19] and **5d**^[19]), 3/1'-iodoferrocenemethanols (**3e**^[19] and **5e**^[19]), 3/1'-iodoferrocenecarboxaldehydes (**3f**^[19] and **5f**^[19]), (3/1'-iodoferrocenyl)phenylketones (**3g**^[19] and **5g**^[19]), 2/3/1'-iodoferrocenecarbonitriles (**1h**,^[20] **3h**^[19] and **5h**^[19]), methyl 3/1'-iodoferrocenecarboxylates (**3i**^[19] and **5i**^[19]), 2/3/1'-iodo-*N,N*-diisopropylferrocenecarboxamides (**1j**,^[19a] **3j**^[19a] and **5j**^[19]), 2/3/1'-iodo-*N,N*-dimethylferrocenamines (**1k**,^[21] **3k**^[19] and **5k**^[19]), *N*-(*tert*-butoxycarbonyl)-3/1'-iodoferrocenamines (**3l**^[19] and **5l**^[19]), and 1-fluoro-2/3-iodoferrocenes (**1m**^[19c] and **3m**^[19c]) were prepared as described previously.

Crystallography. The X-ray diffraction data were collected for the compounds **2b**, **6b**, **6f**, **2i**, **4i**, **4j** and **6j** at 150(2) K on a D8 VENTURE Bruker AXS diffractometer equipped with a (CMOS) PHOTON 100 detector by using $\text{Mo-K}\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$; multilayer monochromator). The structures were solved by dual-space algorithm using the *SHELXT* program,^[38] and then refined with full-matrix least-square methods based on F^2 (*SHELXL*).^[39] All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. Except hydrogen atoms linked to nitrogen atoms that were introduced in the structural model through Fourier difference maps analysis, H atoms were finally included in their calculated positions and treated as riding on their parent atom with constrained thermal parameters. The molecular diagrams were generated by ORTEP-3 (version 2.02).^[40]

1-(N,N-Diisopropylaminomethyl)-2-iodoferrocene (1c, racemic mixture). The protocol was adapted from a previously reported procedure.^[41] To a stirred solution of 2-iodo-*N,N*-diisopropylferrocenecarboxamide^[19a] (**1j**, 6.8 mmol, 3.0 g) in THF (70 mL) under argon was added $\text{BH}_3\cdot\text{THF}$ (34 mmol, 34 mL of a 1.0 M solution). The mixture was refluxed for 16 h, cooled to room temperature, quenched by 10% aqueous KOH (35 mL) and refluxed for 10 h. The resulting solution was cooled to room temperature. Brine (50 mL) was added before extraction with Et_2O (3 x 20 mL), drying over MgSO_4 , concentration under reduced pressure, and purification by chromatography over silica gel (eluent: heptane-AcOEt 60:40 to 0:100). The compound **1c** was isolated in 72% yield as an orange oil: IR (ATR): 805, 819, 953, 1000, 1106, 1151, 1181, 1203, 1361, 1381, 1461, 1676, 2961 cm^{-1} ; ^1H NMR (CDCl_3) δ 1.02 (d, 6H, $J = 6.7 \text{ Hz}$, 2Me), 1.03 (d, 6H, $J = 6.7 \text{ Hz}$, 2Me), 3.02 (sept, 2H, $J = 6.7 \text{ Hz}$, 2CHMe₂), 3.39 (d, 1H, $J = 14.5 \text{ Hz}$, CHH), 3.59 (d, 1H, $J = 14.5 \text{ Hz}$, CHH), 4.11 (s, 5H, Cp), 4.14 (t, 1H, $J = 2.3 \text{ Hz}$, H4), 4.32 (br s, 1H, H5), 4.38 (dd, 1H, $J = 2.3$ and 1.4 Hz , H3); ^{13}C NMR (CDCl_3) δ 20.6 (2CH₃), 21.6 (2CH₃), 44.6 (CH₂), 45.4 (C, C2, C-I), 47.3 (2CH, CHMe₂), 68.2 (CH, C4), 69.1 (CH, C5), 71.7 (5CH, Cp), 74.1 (CH, C3), 89.4 (C, C1, C-CH₂); MS (EI, 70 eV): 425 [M], 325 [M-NiPr₂]. *1-Iodo-2-methylferrocene (1b, racemic mixture)* also formed and was similarly isolated in 18% yield as an orange oil: IR (ATR): 802, 818, 941, 989, 1000, 1030, 1105, 1362, 1380, 1454, 2916, 3092 cm^{-1} ; ^1H NMR (CDCl_3) δ 2.02 (s, 3H, Me), 4.10 (s, 6H, Cp and H4), 4.16 (dd, 1H, $J = 2.4$ and 1.4 Hz , H3), 4.35 (dd, 1H, $J = 2.4$ and 1.4 Hz , H5); ^{13}C NMR (CDCl_3) δ 15.9 (CH₃), 46.6 (C, C1, C-I), 67.8 (CH, C4), 68.1 (CH, C3), 71.7 (5CH, Cp), 73.9 (CH, C5), 86.0 (C, C2, C-Me); MS (EI, 70 eV): 326 [M]. The spectral data are similar to those reported previously.^[42]

2-Iodoferrocenecarboxaldehyde (1f, racemic mixture) was prepared as described previously under the exclusion of light.^[20] It was obtained (eluent: heptane- $\text{CH}_2\text{Cl}_2\text{-Et}_3\text{N}$ 75:15:10) as a red oil: IR (ATR) 747, 817, 953, 1002, 1107, 1247, 1363, 1394, 1431, 1665, 2763, 2835, 2922, 3096 cm^{-1} ; ^1H NMR (CDCl_3) δ 4.28 (s, 5H, Cp), 4.69 (t, 1H, $J = 2.4 \text{ Hz}$, H4), 4.83 (dd, 1H, $J = 2.2$ and 1.2 Hz , H3), 4.90 (dd, 1H, $J = 2.4$ and 1.2 Hz , H5), 10.04 (s, 1H, CHO); ^{13}C NMR (CDCl_3) δ 42.0 (C, C2, C-I), 67.9 (CH, C5), 72.8 (5CH, Cp), 73.9 (CH, C4), 76.9 (C, C1, C-CHO), 79.8 (CH, C3), 194.7 (CHO); MS (EI, 70 eV): 340 [M], 212 [M-HI]. These data are similar to those reported previously.^[20]

(2-Iodoferrocenyl)phenylketone (1g, racemic mixture) was prepared as reported previously.^[20] It was isolated (eluent: heptane-AcOEt 90:10) as a red oil: IR (ATR) 721, 796, 824, 857, 910, 985, 1001, 1026, 1046, 1065, 1107, 1156, 1175, 1190, 1250 (s), 1316, 1352, 1370, 1418, 1446, 1576, 1597, 1641 (s), 2247, 3087 cm^{-1} ; ^1H NMR (CDCl_3) δ 4.24 (s, 5H, Cp), 4.53 (t, 1H, $J = 2.4 \text{ Hz}$, H4), 4.62 (dd, 1H, $J = 2.4$ and 1.4 Hz , H5), 4.85 (dd, 1H, $J = 2.4$ and 1.4 Hz , H3), 7.45 (t, 2H, $J = 7.4 \text{ Hz}$, H3' and H5'), 7.56 (t, 1H, $J = 7.4 \text{ Hz}$, H4'), 7.85 (d, 2H, $J = 7.4 \text{ Hz}$, H2' and H6'); ^{13}C NMR (CDCl_3) δ 41.1 (C, C2, C-I), 71.6 (CH, C5), 72.5 (CH, C4), 73.4 (5CH, Cp), 77.8 (C, C1, C-C(=O)Ph), 80.2 (CH, C3), 128.3 (2CH, C3' and C5'), 128.8 (2CH, C2' and C6'), 132.1 (CH, C4'), 139.3 (C, C1', C-C(=O)Fc), 197.9 (C, C=O). The analyses are similar to those reported previously.^[20]

2-Iodoferrocenecarbonitrile (1h, racemic mixture) was prepared as reported previously.^[20] After purification by column chromatography over silica gel (eluent: hexane-AcOEt 98:2), it was obtained as an orange solid: mp 134-135 °C; IR (ATR) 817, 827, 846, 948, 999, 1030, 1106, 1239, 1362, 1378, 1409, 2227 (s), 3111 cm^{-1} ; ^1H NMR (CDCl_3) δ 4.35 (s, 5H, Cp), 4.41 (t, $J = 2.6 \text{ Hz}$, H4), 4.65 (dd, $J = 2.6$ and 1.2 Hz , H3), 4.71 (dd, $J = 2.6$ and 1.2 Hz , H5); ^{13}C NMR (CDCl_3) δ 41.6 (C, C2, C-I), 59.2 (C, C1, C-CN), 71.7 (CH, C4), 72.1 (CH, C5), 73.7 (5CH, Cp), 77.4 (CH, C3), 119.5 (C, C=N); MS (EI, 70 eV): 337 [M], 209 [M-HI]. The NMR data are similar to those reported previously.^[20]

Methyl 2-iodoferrocenecarboxylate (1i, racemic mixture) was prepared as reported previously.^[20] It was isolated (eluent: heptane-AcOEt 80:20) as an orange oil: IR (ATR) 770, 790, 822, 908, 992, 1058, 1106, 1144, 1191, 1254, 1272, 1328, 1370, 1418, 1445, 1707, 2948, 3097 cm^{-1} ; ^1H NMR (CDCl_3) δ 3.84 (s, 3H, Me), 4.21 (s, 5H, Cp), 4.43 (s, 1H, H4), 4.69 (s, 1H, H3), 4.84 (s, 1H, H5); ^{13}C NMR (CDCl_3) δ 39.8 (C, C2, C-I), 51.7 (CH₃), 70.3 (CH, C5), 71.1 (C, C1, C-CO₂Me), 72.3 (CH, C4), 72.9 (5CH, Cp), 79.8 (CH, C3), 170.8 (C, C=O); MS (EI, 70 eV): 370 [M]. The NMR data are similar to those reported previously.^[20]

2-Iodoferrocenemethanol (1e, racemic mixture). The protocol was adapted from a previously reported procedure.^[43] To a stirred solution of methyl 2-iodoferrocenecarboxylate (**1i**; 1.85 g, 5.0 mmol) in THF (20 mL) at 0 °C was added dropwise a 1.0 M DIBAL-H solution in heptane (20 mL, 20 mmol). The mixture was stirred at this temperature for 1 h before quenching by addition of MeOH (5 mL), dilution with Et_2O (50 mL), and addition of an aqueous saturated solution of sodium and potassium tartrate (50 mL) at 0 °C. After stirring for 30 min at room temperature, extraction with Et_2O and drying over anhydrous Na_2SO_4 , the solvent was evaporated under reduced pressure, and purification by flash chromatography on silica gel (eluent: 88:12 heptane-AcOEt) gave the iodide **1e** in 93% yield (1.6 g): IR (ATR) 683, 752, 815, 940, 973, 995, 1061, 1067, 1103, 1246, 1309, 1365, 1385, 1703, 2857, 2930, 3089, 3254 cm^{-1} ; ^1H NMR ($(\text{CD}_3)_2\text{CO}$) δ 3.90 (t, 1H, $J = 5.9 \text{ Hz}$, OH), 4.15 (s, 5H, Cp), 4.24 (t, 1H, $J = 2.3 \text{ Hz}$, H5), 4.37 (s, 1H, H3), 4.38-4.44 (m, 3H, H4 and CH₂); ^{13}C NMR ($(\text{CD}_3)_2\text{CO}$) δ 44.1 (C, C2, C-I), 61.2 (CH₂), 68.6 (CH, C3), 69.5 (CH, C5), 72.1 (5CH, Cp), 75.4 (CH, C4), 89.8 (C, C1, C-CH₂OH); MS (EI, 70 eV): 342 [M], 138. These data are similar to those reported previously.^[44]

1-Iodo-2-(methoxymethyl)ferrocene (1d, racemic mixture). The protocol was adapted from a previously reported procedure.^[45] 2-Iodoferrocenemethanol (**1e**; 0.68 g, 2.0 mmol) was dissolved in a 4:1 MeOH-AcOH mixture (20 mL), and the solution was heated under reflux

for 2 h (complete conversion of the substrate). After evaporation, the crude was dissolved in methanol (10 mL). The solution was treated by NaOH (0.40 g, 10 mmol) and heated under reflux in order to convert the acetate also formed into 2-iodoferrocenemethanol and separate it easily by chromatography over silica gel. The product **1d** was obtained (eluent: 90:10 heptane-AcOEt) in 64% yield as described previously^[45] as an orange oil. Alternatively, it can also be prepared by following this protocol: NaH (60% dispersion in oil, 72 mg, 2.4 mmol) was added to a cooled (0 °C) solution of 2-iodoferrocenemethanol (**1e**; 0.27 g, 0.80 mmol) in THF (5 mL). After addition, the reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was cooled to 0 °C, iodomethane (0.34 g, 2.4 mmol) was added and the reaction mixture was stirred at rt for 1 h. The reaction mixture was cooled to 0 °C and aqueous saturated NH₄Cl was added. The reaction mixture was extracted with AcOEt. The combined organic layer was dried over MgSO₄, filtrated over cotton wool and concentrated under vacuum using a rotary evaporator to give the crude product. This was purified by purification by flash chromatography on silica gel (eluent: 88:12 heptane-AcOEt) to give the title product in a 89% yield: IR (ATR) 743, 807, 820, 900, 941, 1000, 1030, 1060, 1090, 1159, 1189, 1236, 1374, 1447, 1645, 2814, 2881, 2921, 2978, 3093 cm⁻¹; ¹H NMR (CDCl₃) δ 3.36 (s, 3H, Me), 4.12 (s, 5H, Cp), 4.24 (t, 1H, J = 2.5 Hz, H₄), 4.30 (d, 1H, J = 11.6 Hz, CHH), 4.32-4.34 (m, 2H, H₃ and CHH), 4.46 (br s, 1H, H₅); ¹³C NMR (CDCl₃) δ 45.0 (C, C1, C-1), 58.2 (CH₃), 68.7 (CH, C₃), 69.4 (CH, C₄), 70.7 (CH₂), 71.5 (5CH, Cp), 75.3 (CH, C₅), 84.7 (C, C₂, C-CH₂); MS (EI, 70 eV): 356 [M]. These data are similar to those reported previously.^[45]

1-Azidocarbonyl-2-iodoferrocene (racemic mixture) was prepared by adapting a reported procedure.^[19] Triethylamine (2.8 mL, 20 mmol) was added to a solution of 2-iodoferrocenecarboxylic acid (1.4 g, 4.0 mmol) in dichloromethane (5 mL) at 40 °C. Diphenyl Phosphoryl azide (0.95 mL, 4.4 mmol) was next added dropwise to the reaction mixture which was then kept at the same temperature for 10 min. The reaction mixture was cooled to room temperature and 1.0 M aqueous hydrochloric acid (20 mL) was added. The reaction mixture was extracted with Et₂O (2 x 20 mL) and the combined organic layers were dried over MgSO₄, filtrated over cotton wool and concentrated under vacuum using a rotary evaporator to give the crude product. This was purified by column chromatography over silica gel (eluent: pentane-Et₂O 80:20; R_f = 0.65) to give 1-azidocarbonyl-2-iodoferrocene in 93% yield (1.4 g) as a red solid: mp 58-60 °C; IR (ATR) 667, 739, 752, 820, 895, 1002, 1011, 1042, 1079, 1107, 1122, 1177 (s), 1240, 1256, 1323, 1352, 1370, 1386, 1424, 1685 (s), 2131 (s), 2198, 2263, 3099 cm⁻¹; ¹H NMR (CDCl₃) δ 4.26 (s, 5H, Cp), 4.52 (t, 1H, J = 2.7 Hz, H₄), 4.80-4.81 (m, 2H, H₃ and H₅); ¹³C NMR (CDCl₃) δ 39.2 (C, C₂, C-1), 70.9 (CH, C₃ or C₅), 71.5 (C, C₁, C-CON₃), 73.3 (5CH, Cp), 73.5 (CH, C₄), 81.3 (CH, C₃ or C₅), 176.1 (C, C=O).

1-(tert-Butoxycarbonylamino)-2-iodoferrocene (1f, racemic mixture) was prepared by adapting a reported procedure.^[19] *tert*-Butanol (1.35 mL, 14 mmol) was added to a solution of 1-azidocarbonyl-2-iodoferrocene (1.0 g, 2.8 mmol) in toluene (23 mL) at room temperature and the reaction mixture was heated at 110 °C for 1 h. The reaction mixture was cooled to room temperature and volatiles were removed under reduced pressure. Purification by column chromatography over silica gel (eluent: petroleum ether-AcOEt 95:5) gave **1f** in 41% yield (0.50 g) as an orange solid: R_f (petroleum ether-AcOEt 95:5) = 0.40; mp 114-115 °C; IR (ATR) 668, 690, 772, 810, 827, 874, 978, 999, 1020, 1049, 1077, 1104, 1163, 1254, 1359 (s), 1432, 1489, 1691 (s), 2970, 3249 cm⁻¹; ¹H NMR (CDCl₃) δ 1.53 (s, 9H, *t*Bu), 4.10 (t, 1H, J = 2.5 Hz, H₄), 4.14 (s, 5H, Cp), 4.24 (dd, 1H, J = 2.3 and 1.5 Hz, H₃), 4.92 (br s, 1H, H₅), 5.75 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 28.5 (3CH₃, CMe₃), 37.7 (C, C₂, C-1), 60.2 (CH, C₅), 65.6 (CH, C₄), 69.6 (CH, C₃), 72.2 (5CH, Cp), 80.7 (C, CMe₃), 96.8 (C, C₁, C-N), 153.2 (C, C=O); MS (EI, 70 eV): 353 [M-*t*BuO+H], 197.

General procedure 1. The iodoferrrocene (unless otherwise specified in the product description, 1.0 mmol), CuI (0.19 g, 1.0 mmol), K₃PO₄ (0.42 g, 2.0 mmol), DMEDA (0.11 mL, 1.0 mmol) and acetamide (65 mg, 1.1 mmol) were introduced in a degassed Schlenk tube and dissolved in dioxane (2 mL). The mixture was stirred under argon and heated at 90 °C for 14 h. It

was then allowed to cool to room temperature before addition of water (10 mL). After extraction with AcOEt (3 x 20 mL), drying over MgSO₄ and evaporation of the solvent under reduced pressure, the coupling product was purified by chromatography over silica gel (the eluent is given in the product description).

N-(2-Methylferrocenyl)acetamide (2b, stereoisomeric mixture due to rotamers).^[46] The general procedure 1 from 1-iodo-2-methylferrocene (**1b**; 0.33 g) gave **2b** (eluent: hexane-AcOEt 60:40) in 61% yield (0.16 g) as an orange solid: mp 156-158 °C; IR (ATR) 800, 1001, 1029, 1103, 1270, 1282, 1368, 1482, 1545, 1646, 2917, 3046, 3226 cm⁻¹; ¹H NMR (CDCl₃, * used for the minor compound) δ 1.79* and 2.09 (2s, 3H, Me-C=O), 1.95 and 1.99* (2s, 3H, Me-Cp), 3.94 and 3.97* (2s, 1H, H₄), 4.00 and 4.08* (2s, 1H, H₃), 4.08 and 4.11* (2s, 5H, Cp), 4.22* and 4.67 (2s, 1H, H₅), 6.63 and 6.95* (2br s, 1H, NH); ¹³C NMR (CDCl₃, * used for the minor compound) δ 12.5* and 12.8 (CH₃, Me-Cp), 19.9* and 24.0 (CH₃, Me-C=O), 63.5 and 66.9* (CH, C₅), 63.5 and 67.8* (CH, C₄), 64.4* and 66.6 (CH, C₃), 69.9 and 70.1* (5CH, Cp), 77.3 and 81.6* (C, C₂, C-Me), 92.1* and 92.8 (C, C₁, C-N), 169.1 and 174.6* (C, C=O); MS (EI, 70 eV): 257 [M], 215 [M-CH₃CO+H], 192 [M-Cp]; HRMS (ESI, *m/z*): calcd. for C₁₃H₁₆FeNO 258.05758, found 258.0569 (3 ppm) [M+H]⁺. **Crystal data for 2b.** C₁₃H₁₆FeNO, *M* = 257.11, *T* = 150(2) K, triclinic, *P*-1, *a* = 8.9219(11), *b* = 11.5613(14), *c* = 12.0385(14) Å, *α* = 69.424(4)°, *β* = 82.673(5)°, *γ* = 81.623(5)°, *V* = 1146.2(2) Å³, *Z* = 4, *d* = 1.490 g cm⁻³, *μ* = 1.292 mm⁻¹. A final refinement on *F*² with 5243 unique intensities and 300 parameters converged at *ωR*(*F*²) = 0.1268 (*R*(*F*) = 0.0506) for 4418 observed reflections with *I* > 2σ(*I*). CCDC 2026533.

N-(3-Methylferrocenyl)acetamide (4b, stereoisomeric mixture due to rotamers). The general procedure 1 from 1-iodo-3-methylferrocene (**3b**; 0.33 g) gave **4b** (eluent: petroleum ether-AcOEt 50:50; R_f = 0.26) in 65% yield (0.17 g) as an orange oil: IR (ATR) 666, 751, 810, 928, 945, 968, 1000, 1030, 1105, 1138, 1200, 1268, 1285, 1349, 1374, 1454, 1491, 1563, 1651, 2177, 2922, 3093, 3269 cm⁻¹; ¹H NMR (CDCl₃, * used for the minor compound) δ 1.88 and 1.94* (2s, 3H, Me-Cp), 1.89* and 2.03 (2s, 3H, Me-C=O), 3.94 and 4.00* (2s, 1H, H₄), 4.10 and 4.12* (2s, 5H, Cp), 4.16* and 4.43 (2s, 1H, H₅), 4.21* and 4.58 (2s, 1H, H₂), 6.77 (br s, 1H, NH); ¹³C NMR (CDCl₃, * used for the minor compound) δ 14.8* and 14.8 (CH₃, Me-Cp), 20.3* and 24.1 (CH₃, Me-C=O), 60.8 and 66.0* (CH, C₅), 63.6 and 68.1* (CH, C₂), 65.6 and 67.2* (CH, C₄), 70.1 and 70.2* (5CH, Cp), 81.0 and 82.5* (C, C₃, C-Me), 92.3* and 94.2 (C, C₁, C-N), 168.5 and 173.9* (C, C=O); MS (EI, 70 eV): 257 [M], 215 [M-CH₃CO+H], 192 [M-Cp]; HRMS (ESI, *m/z*): calcd. for C₁₃H₁₆FeNO 258.05758, found 258.05675 (3 ppm) [M+H]⁺.

N-(1'-Methylferrocenyl)acetamide (6b). The general procedure 1 from 1-iodo-1'-methylferrocene (**5b**; 0.14 g, 0.43 mmol) gave **6b** (eluent: hexane-AcOEt 60:40) in 80% yield (90 mg) as an orange solid: mp 98-100 °C; IR (ATR) 746, 803, 1021, 1037, 1286, 1371, 1384, 1477, 1574, 1652, 2854, 2921, 3088, 3212, 3259 cm⁻¹; ¹H NMR (CDCl₃) δ 1.95 (s, 3H, Me-Fc), 2.05 (s, 3H, Me-C=O), 4.01 (s, 2H, H₃ and H₄), 4.07 (s, 2H, H_{3'} and H_{4'}), 4.10 (s, 2H, H_{2'} and H_{5'}), 4.58 (s, 2H, H₂ and H₅), 6.87 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 13.9 (CH₃, Me-Fc), 24.1 (CH₃, Me-C=O), 62.0 (2CH, C₂ and C₅), 65.6 (2CH, C₃ and C₄), 68.6 (2CH, C_{3'} and C_{4'}), 70.6 (2CH, C_{2'} and C_{5'}), 85.5 (C, C_{1'}, C-Me), 96.1 (C, C₁, C-N), 168.3 (C, C=O); MS (EI, 70 eV): 257 [M], 215 [M-CH₃CO+H], 178; HRMS (ESI, *m/z*): calcd. for C₁₃H₁₆FeNO 258.05758, found 258.0568 (3 ppm) [M+H]⁺. **Crystal data for 6b.** C₁₃H₁₆FeNO, *M* = 257.11, *T* = 150(2) K, monoclinic, *P*2₁, *a* = 5.9727(11), *b* = 7.4595(14), *c* = 25.351(4) Å, *β* = 93.547(7)°, *V* = 1127.3(4) Å³, *Z* = 4, *d* = 1.515 g cm⁻³, *μ* = 1.313 mm⁻¹. A final refinement on *F*² with 5158 unique intensities and 301 parameters converged at *ωR*(*F*²) = 0.0654 (*R*(*F*) = 0.0261) for 4955 observed reflections with *I* > 2σ(*I*). CCDC 2026534.

N-(3-(Diisopropylaminomethyl)ferrocenyl)acetamide (4c, racemic mixture). The general procedure 1 from 1-(diisopropylaminomethyl)-3-iodoferrocene (**3c**; 0.21 g, 0.50 mmol) gave **4c** (eluent: heptane-AcOEt-Et₃N 59:40:1) in 66% yield (0.12 g) as an orange oil: IR (ATR) 729, 814,

908, 1001, 1105, 1162, 1200, 1361, 1377, 1567, 1655, 2964, 3096, 3276 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 0.99 (d, 6H, $J = 6.7$ Hz, 2Me), 1.01 (d, 6H, $J = 6.7$ Hz, 2Me), 2.04 (s, 3H, Me-C=O), 3.05 (sept, 2H, $J = 6.7$ Hz, 2CHMe₂), 3.38 (d, 1H, $J = 14.5$ Hz, CHH), 3.44 (d, 1H, $J = 14.5$ Hz, CHH), 4.04 (s, 1H, H4), 4.10 (s, 5H, Cp), 4.51 (s, 1H, H5), 4.66 (s, 1H, H2), 6.75 (br s, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3) δ 20.8 (2CH₃), 20.9 (2CH₃), 24.2 (CH₃, Me-C=O), 44.2 (CH₂), 47.8 (2CH, CHMe₂), 60.8 (CH, C5), 63.1 (CH, C2), 65.9 (CH, C4), 69.8 (5CH, Cp), 84.6 (C, C3, C-CH₂), 94.1 (C, C1, C-N), 168.2 (C, C=O); HRMS (ESI, m/z): calcd. for C₁₉H₂₉FeN₂O 357.16238, found 357.16185 (2 ppm) [$\text{M}+\text{H}$]⁺.

N-(1'-*(Diisopropylaminomethyl)ferrocenyl*)acetamide (**6c**). The general procedure 1 from 1-(*N,N*-diisopropylaminomethyl)-1'-iodoferrocene (**5c**; 0.22 g, 0.5 mmol) gave **6c** (eluent: heptane-AcOEt 60:40) in 52% yield (90 mg) as an orange solid: mp 68-70 °C; IR (ATR) 720, 805, 930, 1018, 1170, 1202, 1275, 1374, 1479, 1553, 1654, 2961, 3290 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 0.99 (d, 12H, $J = 6.5$ Hz, 4Me), 2.06 (s, 3H, Me-C=O), 3.03 (sept, 2H, $J = 6.7$ Hz, 2CHMe₂), 3.42 (s, 2H, CH₂), 3.93 (s, 2H, H3 and H4), 4.04 (s, 2H, H3' and H4'), 4.16 (s, 2H, H2' and H5'), 4.51 (s, 2H, H2 and H5), 6.79 (s, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3) δ 20.9 (4CH₃), 24.2 (CH₃, Me-C=O), 43.4 (CH₂), 47.6 (2CH, CHMe₂), 62.1 (2CH, C2 and C5), 65.2 (2CH, C3 and C4), 68.6 (2CH, C3' and C4'), 70.8 (2CH, C2' and C5'), 89.1 (C, C1', C-CH₂), 94.6 (C, C1, C-N), 168.3 (C, C=O); HRMS (ESI, m/z): calcd. for C₁₉H₂₉FeN₂O 357.16238, found 357.16225 (0 ppm) [$\text{M}+\text{H}$]⁺.

N-(2-(Methoxymethyl)ferrocenyl)acetamide (**2d**, racemic mixture). The general procedure 1 from 1-iodo-2-(methoxymethyl)ferrocene (**1d**; 0.36 g) gave **2d** (eluent: hexane-AcOEt 60:40) in 61% yield (0.18 g) as an orange solid: mp 116-118 °C; IR (ATR) 704, 804, 999, 1032, 1090, 1189, 1273, 1305, 1373, 1448, 1543, 1651, 2926, 3274 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 2.03 (s, 3H, Me-C=O), 3.35 (s, 3H, OMe), 3.92 (s, 1H, H4), 3.95 (s, 1H, H3), 4.10 (s, 5H, Cp), 4.16 (d, 1H, $J = 11.4$ Hz, CHH), 4.52 (d, 1H, $J = 11.4$ Hz, CHH), 5.01 (s, 1H, H5), 7.39 (br s, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3) δ 24.2 (CH₃, Me-C=O), 58.1 (CH₃, OMe), 62.9 (CH, C5), 63.9 (CH, C3), 64.9 (CH, C4), 69.6 (5CH, Cp), 69.8 (CH₂), 74.1 (C, C2, C-CH₂), 94.4 (C, C1, C-N), 168.4 (C, C=O); MS (EI, 70 eV): 287 [M]; HRMS (ESI, m/z): calcd. for C₁₄H₁₇FeNO₂ 287.06032, found 287.0596 (3 ppm) M⁺.

N-(3-(Methoxymethyl)ferrocenyl)acetamide (**4d**, racemic mixture). The general procedure 1 from 1-iodo-3-(methoxymethyl)ferrocene (**3d**; 0.36 g) gave **4d** (eluent: hexane-AcOEt 60:40) in 51% yield (0.15 g) as an orange oil: IR (ATR) 731, 815, 1001, 1082, 1104, 1271, 1373, 1448, 1494, 1563, 1654, 2927, 3094, 3271 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 2.02 (s, 3H, Me-C=O), 3.29 (s, 3H, OMe), 4.07 (s, 1H, H4), 4.12 (s, 5H, Cp), 4.14-4.18 (m, 2H, CH₂), 4.59 (s, 1H, H5), 4.70 (s, 1H, H2), 7.28 (br s, 1H, NH); $^{13}\text{C NMR}$ (CDCl_3) δ 24.0 (CH₃, Me-C=O), 57.7 (CH₃, OMe), 61.8 (CH, C5), 62.7 (CH, C2), 65.8 (CH, C4), 69.8 (5CH, Cp), 70.9 (CH₂), 79.7 (C, C3, C-CH₂), 95.3 (C, C1, C-N), 168.6 (C, C=O); MS (EI, 70 eV): 287 [M], 192; HRMS (ESI, m/z): calcd. for C₁₄H₁₇FeNO₂ 287.06032, found 287.0599 (2 ppm) M⁺.

N-(1'-Methoxymethylferrocenyl)acetamide (**6d**). The general procedure 1 from 1-iodo-1'-(methoxymethyl)ferrocene (**5d**; 0.36 g) gave **6d** (eluent: heptane-AcOEt 60:40; Rf = 0.80) in 67% yield (0.19 g) as an orange solid: mp 66-68 °C; IR (ATR) 750, 772, 792, 810, 948, 1039, 1084, 1192, 1239, 1279, 1368, 1386, 1484, 1569, 1653, 2827, 2891, 2924, 3104, 3265 cm^{-1} ; $^1\text{H NMR}$ ($(\text{CD}_3)_2\text{SO}$) δ 1.91 (s, 3H, Me-C=O), 3.16 (s, 3H, OMe), 3.92 (t, 2H, $J = 1.8$ Hz, H3 and H4), 4.09 (t, 2H, $J = 1.6$ Hz, H2' and H5'), 4.12 (t, 2H, $J = 1.6$ Hz, H3' and H4'), 4.13 (s, 2H, CH₂), 4.52 (t, 2H, $J = 1.8$ Hz, H2 and H5), 9.25 (s, 1H, NH); $^{13}\text{C NMR}$ ($(\text{CD}_3)_2\text{SO}$) δ 23.4 (CH₃, Me-C=O), 56.8 (CH₃, OMe), 60.8 (2CH, C2 and C5), 64.1 (2CH, C3 and C4), 68.8 (2CH, C2' and C5'), 69.6 (CH₂), 70.3 (2CH, C3' and C4'), 83.1 (C, C1', C-CH₂), 96.1 (C, C1, C-N), 167.8 (C, C=O); MS (EI, 70 eV): 287 [M], 209, 179; HRMS (ESI, m/z): calcd. for C₁₄H₁₇FeNO₂ 287.06032, found 287.0598 (2 ppm) M⁺.

N-(3-(Hydroxymethyl)ferrocenyl)acetamide (**4e**, racemic mixture). The general procedure 1 from 3-iodoferrocenemethanol (**3e**; 0.34 g) gave **4e** (eluent: AcOEt; Rf = 0.36) in 25.5% yield (70 mg) as a light yellow solid:

mp 182-184 °C; IR (ATR) 709, 803, 823, 944, 971, 989, 1024, 1039, 1102, 1141, 1174, 1281, 1301, 1345, 1380, 1446, 1492, 1576, 1639, 2864, 2950, 3081 cm^{-1} ; $^1\text{H NMR}$ ($(\text{CD}_3)_2\text{SO}$) δ 1.88 (s, 3H, Me-C=O), 3.94 (t, 1H, $J = 1.8$ Hz, H4), 4.05 (s, 5H, Cp), 4.12 (dd, 1H, $J = 12.1$ and 5.8 Hz, CHH), 4.14 (dd, 1H, $J = 12.1$ and 5.8 Hz, CHH), 4.44 (t, 1H, $J = 1.8$ Hz, H5), 4.62 (s, 1H, H2), 4.72 (t, 1H, $J = 5.8$ Hz, OH), 9.21 (br s, 1H, NH); $^{13}\text{C NMR}$ ($(\text{CD}_3)_2\text{SO}$) δ 23.4 (CH₃, Me), 59.3 (CH₂), 60.2 (CH, C5), 61.5 (CH, C2), 63.9 (CH, C4), 69.2 (5CH, Cp), 84.2 (C, C3, C-CH₂OH), 95.2 (C, C1, C-NHCOMe), 167.9 (C, C=O); HRMS (ESI, m/z): calcd. for C₁₃H₁₅FeNO₂ 273.04467, found 273.0442 (2 ppm) M⁺.

N-(1'-Hydroxymethylferrocenyl)acetamide (**6e**). The general procedure 1 from 1'-iodoferrocenemethanol (**5e**; 0.34 g) gave **6e** (eluent: petroleum ether-AcOEt 50:50) in 18% yield (49 mg) as an orange solid: mp 152-154 °C; IR (ATR) 715, 739, 761, 816, 832, 849, 922, 964, 990, 1012, 1028, 1039, 1176, 1235, 1261, 1289, 1339, 1353, 1390, 1454, 1477, 1570, 1648, 1732, 2147, 2187, 2851, 2921, 2951, 3086, 3256 cm^{-1} ; $^1\text{H NMR}$ ($(\text{CD}_3)_2\text{SO}$) δ 1.90 (s, 3H, Me), 3.91 (t, 2H, $J = 1.8$ Hz, H3 and H4), 4.04 (t, 2H, $J = 1.7$ Hz, H2' and H5'), 4.08 (t, 2H, $J = 1.7$ Hz, H3' and H4'), 4.18 (t, 2H, $J = 5.8$ Hz, CH₂), 4.50 (t, 2H, $J = 1.8$ Hz, H2 and H5), 4.62 (t, 1H, $J = 5.8$ Hz, OH), 9.23 (s, 1H, NH); $^{13}\text{C NMR}$ ($(\text{CD}_3)_2\text{SO}$) δ 23.4 (CH₃), 58.7 (CH₂), 60.7 (2CH, C2 and C5), 64.0 (2CH, C3 and C4), 68.2 (2CH, C2' and C5'), 69.1 (2CH, C3' and C4'), 88.4 (C, C1', C-CH₂), 95.8 (C, C1, C-N), 167.8 (C, C=O); HRMS (ESI, m/z): calcd. for C₁₃H₁₅FeNO₂ 273.04467, found 273.0441 (2 ppm) M⁺.

N-(2-Formylferrocenyl)acetamide (**2f**, racemic mixture). The general procedure 1 from 2-iodoferrocenecarboxaldehyde (**1f**; 0.34 g) gave **2f** (eluent: petroleum ether-AcOEt 90:10 to 70:30) in 12% yield (33 mg) as a red solid: mp 110-112 °C; IR (ATR) 735, 797, 816, 1001, 1034, 1106, 1233, 1275, 1384, 1435, 1469, 1530, 1652, 2925, 3341 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 2.12 (s, 3H, Me), 4.24 (s, 5H, Cp), 4.40-4.42 (m, 2H, H3 and H4), 5.80 (s, 1H, H5), 8.67 (br s, 1H, NH), 10.06 (s, 1H, CHO); $^{13}\text{C NMR}$ (CDCl_3) δ 24.5 (CH₃, Me), 66.5 (CH, C5), 67.0 (C, C2, C-CHO), 67.2 (C3 or C4), 69.6 (C3 or C4), 70.8 (5CH, Cp), 98.2 (C, C1, C-N), 169.1 (C, Me-C=O), 197.2 (CH, CHO); MS (EI, 70 eV): 271 [M], 229 [M-CH₃CO+H], 207; HRMS (ESI, m/z): calcd. for C₁₃H₁₄FeNO₂ 272.03685, found 272.03665 (1 ppm) [$\text{M}+\text{H}$]⁺. These analyses were found similar to those reported previously.^[47]

N-(3-Formylferrocenyl)acetamide (**4f**, racemic mixture). The general procedure 1 from 3-iodoferrocenecarboxaldehyde (**3f**; 0.34 g) gave **4f** (eluent: petroleum ether-AcOEt 40:60; Rf = 0.17) in 12% yield (33 mg) as an orange oil: IR (ATR) 746, 786, 823, 949, 969, 1003, 1038, 1106, 1139, 1242, 1289, 1329, 1374, 1398, 1439, 1489, 1555, 1651, 1736, 2854, 2925, 3086, 3278 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 2.10 (s, 3H, Me), 4.26 (s, 5H, Cp), 4.66 (dd, 1H, $J = 2.2$ and 1.1 Hz, H5), 5.13 (dd, 1H, $J = 2.2$ and 1.1 Hz, H4), 5.18 (s, 1H, H2), 7.47 (br s, 1H, NH), 9.88 (s, 1H, CHO); $^{13}\text{C NMR}$ (CDCl_3) δ 24.2 (CH₃, Me), 61.2 (CH, C2), 66.5 (C4), 66.8 (C5), 71.0 (5CH, Cp), 75.4 (C, C3, C-CHO), 99.3 (C, C1, C-N), 168.7 (C, Me-C=O), 193.8 (CH, CHO); HRMS (ESI, m/z): calcd. for C₁₃H₁₄FeNO₂ 272.03685, found 272.03674 (0 ppm) [$\text{M}+\text{H}$]⁺.

N-(1'-Formylferrocenyl)acetamide (**6f**). The general procedure 1 from 1'-iodoferrocenecarboxaldehyde (**5f**; 0.34 g) gave **6f** (eluent: hexane-AcOEt 50:50) in 30% yield (80 mg) as a dark orange solid: mp 150-152 °C; IR (ATR) 734, 817, 1023, 1039, 1246, 1288, 1376, 1456, 1486, 1574, 1653, 2782, 2853, 2926, 3091, 3211, 3260 cm^{-1} ; $^1\text{H NMR}$ (CDCl_3) δ 2.09 (s, 3H, Me), 4.05 (t, 2H, $J = 1.8$ Hz, H3 and H4), 4.61 (t, 2H, $J = 1.8$ Hz, H3' and H4'), 4.71 (t, 2H, $J = 1.8$ Hz, H2 and H5), 4.81 (t, 2H, $J = 1.8$ Hz, H2' and H5'), 6.70 (br s, 1H, NH), 9.79 (s, 1H, CHO); $^{13}\text{C NMR}$ (CDCl_3) δ 24.1 (CH₃), 62.5 (2CH, C2 and C5), 66.2 (2CH, C3 and C4), 70.9 (2CH, C2' and C5'), 74.2 (2CH, C3' and C4'), 80.5 (C, C1', C-CHO), 96.4 (C, C1, C-N), 168.7 (C, Me-C=O), 193.3 (CHO); MS (EI, 70 eV): 271 [M], 178 [M-CpCHO]; HRMS (ESI, m/z): calcd. for C₁₃H₁₄FeNO₂ 272.03685, found 272.03655 (1 ppm) [$\text{M}+\text{H}$]⁺. Crystal data for **6f**. C₁₃H₁₄FeNO₂, $M = 271.09$, $T = 150(2)$ K, monoclinic, $P2_1/c$, $a = 7.1408(12)$, $b = 16.661(3)$, $c = 9.5968(17)$ Å, $\beta = 102.302(6)^\circ$, $V = 1115.5(3)$ Å³, $Z = 4$, $d = 1.614$ g cm^{-3} , $\mu = 1.338$ mm⁻¹. A final refinement on F^2 with 2568 unique intensities and 157 parameters

converged at $\omega R(F^2) = 0.0670$ ($R(F) = 0.0292$) for 2199 observed reflections with $I > 2\sigma(I)$. CCDC 2026535.

N-(2-Benzoylferrocenyl)acetamide (**2g**, racemic mixture). The general procedure 1 from (2-iodoferrocenyl)phenylketone (**1g**; 0.42 g) gave **2g** (eluent: hexane-AcOEt 60:40) in 13% yield (45 mg) as a red solid: mp 82–84 °C; IR (ATR) 699, 730, 812, 901, 1004, 1049, 1230, 1286, 1344, 1420, 1524, 1616, 1685, 3335 cm⁻¹; ¹H NMR (CDCl₃) δ 2.17 (s, 3H, Me), 4.17 (s, 5H, Cp), 4.41–4.44 (m, 2H, H3 and H4), 5.89 (s, 1H, H5), 7.49 (t, 2H, $J = 7.4$ Hz, H3' and H5'), 7.59 (t, 1H, $J = 7.4$ Hz, H4'), 7.89 (d, 2H, $J = 7.4$ Hz, H2' and H6'), 9.49 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.8 (CH₃, Me), 65.2 (C, C2, C-C(=O)Ph), 66.3 (CH, C5), 68.3 and 68.9 (2CH, C3 and C4), 71.4 (5CH, Cp), 99.7 (C, C1, C-N), 128.1 (2CH, C2' and C6'), 128.5 (2CH, C3' and C5'), 132.0 (CH, C4'), 139.8 (C, C1', C-C(=O)Fc), 169.2 (C, Me-C=O), 204.4 (C, Ph-C=O); MS (EI, 70 eV): 347 [M], 305 [M-CH₃CO+H], 281; HRMS (ESI, m/z): calcd. for C₁₉H₁₈FeNO₂ 348.06815, found 348.06807 (0 ppm) [M+H]⁺.

N-(3-Benzoylferrocenyl)acetamide (**4g**, racemic mixture). The general procedure 1 from (3-iodoferrocenyl)phenylketone (**3g**; 0.42 g) gave **4g** (eluent: petroleum ether-AcOEt 50:50; Rf = 0.13) in 19% yield (66 mg) as a red solid: mp 30–33 °C; IR (ATR) 670, 697, 725, 823, 859, 910, 972, 1002, 1106, 1125, 1174, 1229, 1298, 1333, 1375, 1425, 1446, 1490, 1560 (s), 1616, 1661, 3085, 3279 cm⁻¹; ¹H NMR (CDCl₃) δ 2.09 (s, 3H, Me), 4.18 (s, 5H, Cp), 4.76 (dd, 1H, $J = 2.5$ and 1.3 Hz, H4), 5.15 (dd, 1H, $J = 2.5$ and 1.3 Hz, H5), 5.30 (t, 1H, $J = 1.3$ Hz, H2), 7.44 (t, 2H, $J = 7.1$ Hz, H3' and H5'), 7.54 (t, 1H, $J = 7.1$ Hz, H4'), 7.80 (br s, 1H, NH), 7.86 (d, 2H, $J = 7.1$ Hz, H2' and H6'); ¹³C NMR (CDCl₃) δ 24.1 (CH₃, Me), 63.3 (CH, C2), 66.2 (CH, C5), 68.6 (CH, C4), 71.6 (5CH, Cp), 74.0 (C, C3, C-COPh), 98.8 (C, C1, C-NHCOMe), 128.1 (2CH, C2' and C6'), 128.4 (2CH, C3' and C5'), 131.8 (CH, C4'), 139.6 (C, C1'), 168.9 (Me-C=O), 199.9 (C, Ph-C=O); MS (EI, 70 eV): 347 [M], 282; MS (EI, 70 eV): 340.07 [M+H]⁺.

N-(1'-Benzoylferrocenyl)acetamide (**6g**). The general procedure 1 from (1'-iodoferrocenyl)phenylketone (**5g**; 0.42 g) gave **6c** (eluent: hexane-AcOEt 60:40) in 25% yield (85 mg) as a red solid: mp 98–100 °C; IR (ATR) 704, 726, 807, 1034, 1055, 1278, 1374, 1440, 1449, 1487, 1570, 1638, 1661, 2851, 2920, 3096, 3216, 3274 cm⁻¹; ¹H NMR (CDCl₃) δ 2.00 (s, 3H, Me), 4.00 (s, 2H, H3 and H4), 4.54 (s, 2H, H2 and H5), 4.59 (s, 2H, H3' and H4'), 4.87 (s, 2H, H2' and H5'), 7.22 (br s, 1H, NH), 7.46 (t, 2H, $J = 7.5$ Hz, H3' and H5'), 7.56 (t, 1H, $J = 7.5$ Hz, H4'), 7.86 (d, 2H, $J = 7.5$ Hz, H2' and H6'); ¹³C NMR (CDCl₃) δ 23.8 (CH₃), 64.8 (2CH, C2 and C5), 66.9 (2CH, C3 and C4), 72.9 (2CH, C2' and C6'), 73.7 (2CH, C3' and C4'), 79.3 (C, C1', C-C(=O)Ph), 94.7 (C, C1, C-N), 128.4 and 128.6 (2 x 2CH, C2' and C6', and C3' and C5'), 132.1 (CH, C4'), 139.4 (C, C-C(=O)Fc), 169.3 (C, Me-C=O), 199.3 (Ph-C=O); MS (EI, 70 eV): 347 [M], 305 [M-CH₃CO+H], 178; HRMS (ESI, m/z): calcd. for C₁₉H₁₈FeNO₂ 348.06815, found 348.06785 (1 ppm) [M+H]⁺.

N-(2-Cyanoferrocenyl)acetamide (**2h**, racemic mixture). The general procedure 1 from 2-iodoferrocenecarbonitrile (**1h**; 0.34 g) gave **2h** (eluent: hexane-AcOEt 60:40) in 24% yield (64 mg) as an orange solid: mp 168–170 °C; IR (ATR) 817, 1001, 1033, 1106, 1244, 1282, 1368, 1472, 1549, 1686, 2223, 3320 cm⁻¹; ¹H NMR (CDCl₃) δ 2.11 (br s, 3H, Me), 4.28 (br s, 7H, Cp, H5, H3 or H4), 5.25 (br s, 1H, H3 or H4), 7.26 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.0 (CH₃, Me), 44.4 (C, C2, C-CN), 65.0, 66.8 and 67.9 (C3, C4 and C5), 71.8 (5CH, Cp), 97.3 (C, C1, C-N), 119.3 (C \equiv N), 169.1 (C, C=O); MS (EI, 70 eV): 268 [M], 226 [M-CH₃CO+H]; HRMS (ESI, m/z): calcd. for C₁₃H₁₃FeN₂O 269.03718, found 269.03666 (2 ppm) [M+H]⁺.

N-(3-Cyanoferrocenyl)acetamide (**4h**, racemic mixture). The general procedure 1 from 3-iodoferrocenecarbonitrile (**3h**; 0.34 g) gave **4h** (eluent: heptane-AcOEt 60:40) in 30% yield (80 mg) as an orange oil: Rf (petroleum ether-AcOEt 50:50) = 0.20; IR (ATR) 822, 1003, 1036, 1107, 1259, 1374, 1422, 1489, 1554, 1661, 2224, 2928, 3094, 3278 cm⁻¹; ¹H NMR (CDCl₃) δ 2.08 (s, 3H, Me), 4.33 (s, 5H, Cp), 4.52 (br s, 1H, H5), 4.83 (br s, 1H, H4), 5.10 (br s, 1H, H2), 7.11 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.1 (CH₃, Me), 48.2 (C, C3, C-CN), 63.7 (CH, C2), 63.8 (CH, C4), 68.5

(CH, C5), 71.9 (5CH, Cp), 96.7 (C, C1, C-N), 120.3 (C \equiv N), 168.6 (C, C=O); MS (EI, 70 eV): 268 [M], 226 [M-CH₃CO+H]; HRMS (ESI, m/z): calcd. for C₁₃H₁₃FeN₂O 269.03718, found 269.0365 (3 ppm) [M+H]⁺.

N-(1'-Cyanoferrocenyl)acetamide (**6h**). The general procedure 1 from 1'-iodoferrocenecarbonitrile (**5h**; 0.34 g) gave **6h** (eluent: heptane-AcOEt 60:40) in 40% yield (0.11 g) as an orange solid: mp 174–176 °C; IR (ATR) 737, 812, 1018, 1029, 1233, 1284, 1376, 1488, 1570, 1660, 2220, 2923, 3089, 3212, 3264 cm⁻¹; ¹H NMR (CDCl₃) δ 2.17 (s, 3H, Me), 4.11 (t, 2H, $J = 1.8$ Hz, H3 and H4), 4.39 (t, 2H, $J = 1.8$ Hz, H3' and H4'), 4.69 (t, 2H, $J = 1.8$ Hz, H2' and H5'), 4.76 (t, 2H, $J = 1.8$ Hz, H2 and H5), 6.84 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.2 (CH₃), 53.7 (C, C1', C-CN), 62.9 (2CH, C2 and C5), 66.9 (2CH, C3 and C4), 71.6 (2CH, C3' and C4'), 72.9 (2CH, C2' and C5'), 96.5 (C, C1, C-N), 119.7 (C, C \equiv N), 169.1 (C, C=O); MS (EI, 70 eV): 268 [M], 226 [M-CH₃CO+H], 178; HRMS (ESI, m/z): calcd. for C₁₃H₁₃FeN₂O 269.03718, found 269.03682 (1 ppm) [M+H]⁺.

N-(2-(Methoxycarbonyl)ferrocenyl)acetamide (**2i**, racemic mixture). The general procedure 1 from methyl 2-iodoferrocenecarboxylate (**1i**; 0.37 g) gave **2i** (eluent: hexane-AcOEt 60:40) in 51% yield (0.15 g) as an orange solid: mp 106–108 °C; IR (ATR) 688, 811, 1035, 1099, 1190, 1232, 1302, 1454, 1536, 1682, 3348 cm⁻¹; ¹H NMR (CDCl₃) δ 2.11 (s, 3H, Me-C=O), 3.85 (s, 3H, CO₂Me), 4.15 (s, 5H, Cp), 4.24 (s, 1H, H4), 4.51 (s, 1H, H5), 5.59 (s, 1H, H3), 8.64 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.6 (CH₃, Me-C=O), 51.8 (CO₂Me), 58.6 (C, C2, C-C=O), 64.7 (CH, C5), 65.0 (CH, C3), 67.3 (CH, C4), 70.8 (5CH, Cp), 98.2 (C, C1, C-N), 168.7 (C, Me-C=O), 175.0 (CO₂Me); MS (EI, 70 eV): 301 [M], 259 [M-CH₃CO+H], 198; HRMS (ESI, m/z): calcd. for C₁₄H₁₆FeNO₃ 302.04741, found 302.04705 (2 ppm) [M+H]⁺. Crystal data for **2i**: C₁₄H₁₅FeNO₃, $M = 301.12$, $T = 150(2)$ K, triclinic, $P-1$, $a = 6.8720(7)$, $b = 9.1004(9)$, $c = 10.9007(10)$ Å, $\alpha = 82.245(3)$, $\beta = 80.996(3)$, $\gamma = 74.205(3)$ °, $V = 644.82(11)$ Å³, $Z = 2$, $d = 1.551$ g cm⁻³, $\mu = 1.172$ mm⁻¹. A final refinement on F^2 with 2941 unique intensities and 177 parameters converged at $\omega R(F^2) = 0.0549$ ($R(F) = 0.0221$) for 2782 observed reflections with $I > 2\sigma(I)$. CCDC 2026536.

N-(3-(Methoxycarbonyl)ferrocenyl)acetamide (**4i**, racemic mixture). The general procedure 1 from methyl 3-iodoferrocenecarboxylate (**3i**; 0.37 g) gave **4i** (eluent: AcOEt-petroleum ether 60:40; Rf = 0.25) in 37% yield (0.11 g) as an orange oil: IR (ATR) 727, 773, 821, 906, 979, 1002, 1096, 1174, 1217, 1299, 1344, 1376, 1423, 1451, 1491, 1558, 1660, 1688, 1710, 2248, 2951, 3095, 3281 cm⁻¹; ¹H NMR (CDCl₃) δ 2.08 (s, 3H, Me-C=O), 3.79 (s, 3H, CO₂Me), 4.20 (s, 5H, Cp), 4.68 (dd, 1H, $J = 2.6$ and 1.4 Hz, H4), 4.90 (dd, 1H, $J = 2.6$ and 1.4 Hz, H5), 5.14 (t, 1H, $J = 1.4$ Hz, H2), 6.73 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.2 (CH₃, Me-C=O), 51.7 (CO₂Me), 62.3 (CH, C2), 64.7 (CH, C5), 67.0 (CH, C4), 67.2 (C, C3, C-C=O), 71.0 (5CH, Cp), 97.1 (C, C1, C-N), 168.4 (C, Me-C=O), 172.4 (CO₂Me); MS (EI, 70 eV): 301 [M], 206; HRMS (ESI, m/z): calcd. for C₁₄H₁₆FeNO₃ 302.04741, found 302.04687 (2 ppm) [M+H]⁺. Crystal data for **4i**: 2(C₁₄H₁₅FeNO₃)·H₂O, $M = 620.25$, $T = 150(2)$ K, monoclinic, Cc , $a = 18.268(4)$, $b = 7.3729(12)$, $c = 21.942(4)$ Å, $\beta = 115.744(6)$ °, $V = 2662.0(8)$ Å³, $Z = 4$, $d = 1.548$ g cm⁻³, $\mu = 1.140$ mm⁻¹. A final refinement on F^2 with 6115 unique intensities and 342 parameters converged at $\omega R(F^2) = 0.0615$ ($R(F) = 0.0253$) for 5947 observed reflections with $I > 2\sigma(I)$. CCDC 2026537.

N-(1'-(Methoxycarbonyl)ferrocenyl)acetamide (**6i**).^[48] The general procedure 1 from methyl 1'-iodoferrocenecarboxylate (**5i**; 0.37 g) gave **6i** (eluent: hexane-AcOEt 50:50; Rf = 0.85) in 54% yield (0.16 g) as an orange solid: mp 96–96 °C; IR (ATR) 773, 818, 968, 1031, 1143, 1195, 1280, 1370, 1467, 1564, 1657, 1696, 2953, 3095, 3213, 3265, 3450, 3557 cm⁻¹; ¹H NMR (CDCl₃) δ 2.06 (s, 3H, Me-C=O), 3.78 (s, 3H, CO₂Me), 4.01 (s, 2H, H3 and H4), 4.39 (s, 2H, H3' and H4'), 4.59 (s, 2H, H2 and H5), 4.77 (s, 2H, H2' and H5'), 7.17 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.0 (CH₃, Me-C=O), 51.8 (CH₃, CO₂Me), 63.4 (2CH, C2 and C5), 66.4 (2CH, C3 and C4), 71.2 (2CH, C2' and C5'), 72.4 (2CH, C3' and C4'), 95.2 (C, C1, C-N), 168.9 (C, Me-C=O), 171.9 (CO₂Me), C1' not seen; MS (EI, 70 eV): 301 [M], 179 [M-CpNHCOMe]; MS (EI, 70 eV): 302.05 [M+H]⁺.

N-(2-(Diisopropylaminocarbonyl)ferrocenyl)acetamide (**2j**, racemic mixture). The general procedure 1 from *N,N*-diisopropyl-2-iodoferrocenecarboxamide (**1j**; 0.44 g) gave **2j** (eluent: hexane-AcOEt 60:40) in 15% yield (53 mg) as an orange solid: mp 104–106 °C; IR (ATR) 760, 806, 1034, 1161, 1254, 1332, 1368, 1455, 1581, 1684, 2970 cm⁻¹; ¹H NMR (CDCl₃) δ 1.42 (br s, 12H, Me), 2.10 (s, 3H, Me), 3.51 (br s, 1H, CHMe₂), 4.12–4.15 (m, 2H, H3 and H4), 4.17 (s, 5H, Cp), 4.85 (br s, 1H, CHMe₂), 5.53 (dd, 1H, *J* = 2.3 and 1.3 Hz, H5), 9.27 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 21.4 (4CH₃), 24.8 (CH₃), 47.0 and 49.8 (2CH, CHMe₂), 63.9 (CH, C3 or C4), 64.3 (CH, C5), 65.6 (CH, C3 or C4), 66.4 (C, C2, C-C=O), 70.9 (5CH, Cp), 98.8 (C, C1, C-N), 168.7 (C, Me-C=O), 172.0 (C, N-C=O); MS (EI, 70 eV): 370 [M], 305 [M-Cp], 269; HRMS (ESI, *m/z*): calcd. for C₁₉H₂₇FeN₂O₂ 371.14165, found 371.14154 (0 ppm) [M+H]⁺.

N-(3-(Diisopropylaminocarbonyl)ferrocenyl)acetamide (**4j**, racemic mixture). The general procedure 1 from *N,N*-diisopropyl-3-iodoferrocenecarboxamide (**3j**; 0.44 g) gave **4j** (eluent: hexane-AcOEt 50:50) in 77% yield (0.27 g) as an orange solid: mp 168–170 °C; IR (ATR) 760, 806, 823, 895, 943, 976, 1003, 1034, 1054, 1106, 1161, 1198, 1216, 1254, 1272, 1316, 1332, 1368, 1409, 1452, 1497, 1577, 1684, 2971, 3098, 3226 cm⁻¹; ¹H NMR (CDCl₃) δ 1.34 (br s, 12H, Me), 2.06 (s, 3H, Me-C=O), 3.44 (br s, 1H, CHMe₂), 4.20 (s, 5H, Cp), 4.41 (s, 1H, H4), 4.69 (br s, 1H, CHMe₂), 4.83 (s, 1H, H5), 5.03 (s, 1H, H2), 7.70 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 21.3 (4CH₃, CHMe₂), 24.0 (CH₃, Me-C=O), 46.5 (CH, CHMe₂), 49.6 (CH, CHMe₂), 62.7 (CH, C5), 63.3 (CH, C2), 66.3 (CH, C4), 70.9 (5CH, Cp), 76.4 (C, C3, C-C=O), 95.9 (C, C1, C-N), 169.1 (C, N-C=O), 169.7 (C, Me-C=O); MS (EI, 70 eV): 370 [M], 305 [M-Cp]; HRMS (ESI, *m/z*): calcd. for C₁₉H₂₇FeN₂O₂ 371.14165, found 371.14142 (1 ppm) [M+H]⁺. *Crystal data for 4j*. C₁₉H₂₆FeN₂O₂, *M* = 370.27, *T* = 150(2) K, triclinic, *P*-1, *a* = 9.9851(13), *b* = 13.3586(18), *c* = 14.9260(19) Å, *α* = 102.450(5), *β* = 96.929(5), *γ* = 109.697(4)°, *V* = 1789.4(4) Å³, *Z* = 4, *d* = 1.374 g cm⁻³, *μ* = 0.856 mm⁻¹. A final refinement on *F*² with 8084 unique intensities and 449 parameters converged at *ωR*(*F*²) = 0.0911 (*R*(*F*) = 0.0434) for 6640 observed reflections with *I* > 2σ(*I*). CCDC 2026538.

N-(1'-(Diisopropylaminocarbonyl)ferrocenyl)acetamide (**6j**). The general procedure 1 from 1'-iodo-*N,N*-diisopropylferrocenecarboxamide (**5j**; 0.44 g) gave **6j** (eluent: heptane-AcOEt 60:40) in 39% yield (0.15 g) as an orange solid: mp 133–135 °C; IR (ATR) 800, 1025, 1043, 1200, 1321, 1333, 1369, 1463, 1532, 1603, 1672, 2923, 2956, 3294 cm⁻¹; ¹H NMR (CDCl₃) δ 1.12 (d, 6H, *J* = 6.5 Hz, CHMe₂), 1.50 (d, 6H, *J* = 6.5 Hz, CHMe₂), 2.07 (s, 3H, Me-C=O), 3.44 (sept, 1H, *J* = 6.5 Hz, CHMe₂), 4.04 (t, 2H, *J* = 1.9 Hz, H3 and H4), 4.19 (sept, 1H, *J* = 6.5 Hz, CHMe₂), 4.27 (t, 2H, *J* = 1.9 Hz, H3' and H4'), 4.44 (t, 4H, *J* = 1.9 Hz, H2, H5, H2' and H5'), 9.36 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 21.1 (4CH₃, CHMe₂), 23.7 (CH₃, Me-C=O), 46.5 (CH, CHMe₂), 50.6 (CH, CHMe₂), 66.7 (2CH, C3 and C4), 67.7 (2CH), 69.0 (2CH, C3' and C4'), 70.1 (2CH), 83.7 (C, C1', C-CONiPr₂), 92.7 (C, C1, C-N), 170.2 (C, CONiPr₂), 170.5 (C, Me-C=O); MS (EI, 70 eV): 313 [M-NHAc+H], 213 [M-NHAc-NiPr₂+H]; HRMS (ESI, *m/z*): calcd. for C₁₉H₂₇FeN₂O₂ 371.14165, found 371.14145 (1 ppm) [M+H]⁺. *Crystal data for 6j*. C₁₉H₂₆FeN₂O₂, *M* = 370.27, *T* = 150(2) K, monoclinic, *P*₂/c, *a* = 10.8869(16), *b* = 11.0850(19), *c* = 14.529(3) Å, *β* = 90.342(6)°, *V* = 1753.3(5) Å³, *Z* = 4, *d* = 1.403 g cm⁻³, *μ* = 0.874 mm⁻¹. A final refinement on *F*² with 4027 unique intensities and 225 parameters converged at *ωR*(*F*²) = 0.0788 (*R*(*F*) = 0.0334) for 3329 observed reflections with *I* > 2σ(*I*). CCDC 2026539.

N-(3-(Dimethylamino)ferrocenyl)acetamide (**4k**, stereoisomeric mixture due to rotamers). The general procedure 1 from 3-iodo-*N,N*-dimethylferroceneamine (**3k**; 50 mg, 0.15 mmol) gave **4k** (eluent: AcOEt-petroleum ether 60:40; *R*_f = 0.14) in 28% yield (12 mg) as a brown solid: mp 150–154 °C (decomposition); IR (ATR) 716, 798, 810, 823, 893, 952, 974, 994, 1002, 1012, 1043, 1101, 1131, 1177, 1272, 1371, 1421, 1444, 1514, 1536, 1649, 2787, 2849, 2919, 3091, 3260 cm⁻¹; ¹H NMR (CDCl₃, * used for the minor compound) δ 1.89* and 2.03 (2s, 3H, Me-C=O), 2.55* and 2.61 (2s, 6H, NMe₂), 3.64 and 3.71* (2s, 1H, H5), 3.92* and 4.36 (2s, 1H, H2), 4.10* and 4.33 (2s, 1H, H4), 4.24 and 4.26* (2s, 5H, Cp), 6.56 and 6.73* (2br s, 1H, NH); ¹³C NMR (CDCl₃, * used for the minor

compound) δ 20.3* and 24.2 (CH₃, Me-C=O), 42.1* and 42.3 (2CH₃, NMe₂), 50.5 and 54.5* (CH, C2), 51.0 and 52.7* (CH, C5), 56.9 and 62.9* (CH, C4), 68.3 and 68.6* (5CH, Cp), 89.1* and 90.7 (C, C1, C-NHCOMe), 112.4 and 113.4* (C, C3, C-NMe₂), 168.4 and 174.3* (C, Me-C=O); HRMS (ESI, *m/z*): calcd. for C₁₄H₁₈FeN₂O 286.07631, found 286.07608 (1 ppm) M⁺.

N-(2-(tert-Butoxycarbonylamino)ferrocenyl)acetamide (**2l**, racemic mixture). The general procedure 1 from 1-(tert-butoxycarbonylamino)-2-iodoferrocene (**1l**; 0.32 g, 0.75 mmol) gave **2l** (eluent: petroleum ether-AcOEt 50:50; *R*_f = 0.41) in 8.5% yield (23 mg) as a yellow solid: mp 142–144 °C; IR (ATR) 776, 806, 881, 943, 999, 1019, 1049, 1072, 1105, 1157, 1228, 1365, 1533, 1690, 1725, 2973, 3323 cm⁻¹; ¹H NMR (CDCl₃) δ 1.51 (s, 9H, *t*Bu), 2.08 (s, 3H, Me-C=O), 3.87 (s, 1H, H4), 4.19 (s, 5H, Cp), 4.33 (s, 1H, H3), 4.56 (s, 1H, H5), 6.52 (br s, 1H, NH), 7.94 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.2 (CH₃, Me-C=O), 28.4 (3CH₃, Me₃C), 60.2 (CH, C3), 61.0 (CH, C5), 61.2 (CH, C4), 70.5 (5CH, Cp), 80.7 (C, Me₃C), 86.2 (C, C1, C-NHCOMe), 87.8 (C, C2, C-NHCO₂*t*Bu), 154.5 (C, CO₂*t*Bu), 169.2 (C, Me-C=O); HRMS (ESI, *m/z*): calcd. for C₁₇H₂₃FeN₂O₃ 359.10526, found 359.1050 (1 ppm) [M+H]⁺.

N-(3-(tert-Butoxycarbonylamino)ferrocenyl)acetamide (**4l**, racemic mixture). The general procedure 1 from *N*-(tert-butoxycarbonyl)-3-iodoferroceneamine (**3l**; 0.30 g, 0.70 mmol) gave **4l** (eluent: AcOEt-petroleum ether 60:40; *R*_f = 0.36) in 17% yield (43 mg) as an orange solid: mp 206–209 °C (decomposition); IR (ATR) 678, 730, 756, 813, 881, 936, 970, 999, 1028, 1054, 1105, 1155 (s), 1252, 1356, 1366, 1459, 1498, 1567 (s), 1662, 1692, 2979, 3081, 3222 cm⁻¹; ¹H NMR (CD₃CN) δ 1.46 (s, 9H, *t*Bu), 1.91 (s, 3H, Me-C=O), 4.09 (s, 5H, Cp), 4.23 (s, 1H, H4 or H5), 4.29 (s, 1H, H4 or H5), 4.90 (s, 1H, H2), 6.60 (br s, 1H, NH), 7.53 (br s, 1H, NH); ¹³C NMR (CD₃CN) δ 23.7 (CH₃, Me-C=O), 28.5 (3CH₃, Me₃C), 56.0 (CH, C2), 57.2 (CH, C4 or C5), 57.8 (CH, C4 or C5), 70.9 (5CH, Cp), 79.1 (C, CMe₃), 92.6 (C, C1, C-NHCOMe), 94.2 (C, C3, C-NHCO₂*t*Bu), 154.4 (C, CO₂*t*Bu), 169.3 (C, Me-C=O); HRMS (ESI, *m/z*): calcd. for C₁₇H₂₂FeN₂O₃ 358.09743, found 358.0976 (0 ppm) M⁺.

N-(1'-(tert-Butoxycarbonylamino)ferrocenyl)acetamide (**6l**). The general procedure 1 from *N*-(tert-butoxycarbonyl)-1'-iodoferroceneamine (**5l**; 0.30 g, 0.70 mmol) gave **6l** (eluent: petroleum ether-AcOEt 50:50) in 30% yield (80 mg) as an orange solid: mp 82–84 °C; IR (ATR) 670, 701, 726, 793, 816, 826, 860, 926, 1008, 1028, 1055, 1105, 1132, 1155, 1180, 1223, 1293, 1333, 1354, 1368, 1381, 1402, 1422, 1446, 1487, 1574, 1598, 2853, 2923, 3031, 3094 cm⁻¹; ¹H NMR ((CD₃)₂SO) δ 1.44 (s, 9H, *t*Bu), 1.90 (s, 3H, Me-C=O), 3.83 (s, 2H, H3' and H4'), 3.85 (s, 2H, H3 and H4), 4.36 (br s, 2H, H2' and H5'), 4.45 (s, 2H, H2 and H5), 8.23 (s, 1H, NHCO₂*t*Bu), 9.06 (s, 1H, NHCOMe); ¹³C NMR ((CD₃)₂SO) δ 23.4 (CH₃, Me-C=O), 28.2 (3CH₃, CMe₃), 61.0 (2CH, C2' and C5'), 61.6 (2CH, C2 and C5), 64.5 (2CH, C3' and C4'), 64.7 (2CH, C3 and C4), 78.3 (C, CMe₃), 95.5 (C, C1, C-NHCOMe), 96.9 (C, C1', C-NHCO₂*t*Bu), 153.1 (NHCO₂*t*Bu), 167.7 (C, Me-C=O); HRMS (ESI, *m/z*): calcd. for C₁₇H₂₂FeN₂O₃ 358.09743, found 358.0974 (0 ppm) M⁺.

N-(2-Fluoroferrrocenyl)acetamide (**2m**, racemic mixture). The general procedure 1 from 1-fluoro-2-iodoferrocene (**1m**; 0.33 g) gave **2m** (eluent: hexane-AcOEt 60:40) in 34% yield (89 mg) as a dark orange solid: mp 172–174 °C; IR (ATR) 665, 807, 830, 997, 1020, 1104, 1116, 1200, 1265, 1367, 1409, 1456, 1486, 1512, 1657, 1679, 2923, 3306 cm⁻¹; ¹H NMR (CDCl₃) δ 2.12 (s, 3H, Me), 3.66 (br s, 1H, H4), 4.18 (br s, 1H, H3), 4.23 (s, 5H, Cp), 4.65 (br s, 1H, H5), 6.99 (br s, 1H, NH); ¹³C NMR (CDCl₃) δ 24.0 (CH₃, Me), 52.6 (d, CH, *J* = 13.1 Hz, C3), 56.4 (CH, C4), 57.2 (CH, C5), 70.6 (5CH, Cp), 82.7 (d, C, *J* = 10.7 Hz, C1, C-N), 128.3 (d, C, *J* = 269 Hz, C2, C-F), 168.9 (C, Me-C=O); ¹⁹F NMR (CDCl₃) δ -197.4; MS (EI, 70 eV): 261 [M], 219 [M-CH₃CO+H], 198; HRMS (ESI, *m/z*): calcd. for C₁₂H₁₃FFeNO 262.03251, found 262.03212 (2 ppm) [M+H]⁺.

N-(3-Fluoroferrrocenyl)acetamide (**4m**, racemic mixture). The general procedure 1 from 1-fluoro-3-iodoferrocene (**3m**; 0.33 g) gave **4m** (eluent: hexane-AcOEt 60:40) in 57% yield (0.15 g) as an orange solid: mp 100–102 °C; IR (ATR) 707, 763, 808, 836, 888, 921, 947, 964, 1001, 1022,

1107, 1125, 1180, 1264, 1348, 1372, 1410, 1453, 1486, 1559, 1659, 1780, 2931, 3098, 3278 cm⁻¹; ¹H NMR ((CD₃)₂SO) δ 1.43 (s, 3H, Me), 3.73 (s, 1H, H5), 3.76 (s, 5H, Cp), 3.81 (s, 1H, H4), 4.42 (s, 1H, H2), 8.74 (br s, 1H, NH); ¹³C NMR ((CD₃)₂SO) δ 23.3 (CH₃, Me), 49.9 (d, CH, J = 16.8 Hz, C2), 51.2 (d, CH, J = 14.9 Hz, C4), 53.0 (d, CH, J = 2.3 Hz, C5), 70.2 (5CH, Cp), 88.8 (d, C, J = 5.1 Hz, C1, C-N), 132.9 (d, C, J = 267 Hz, C3, C-F), 168.1 (C, Me-C=O); ¹⁹F NMR (CD₃)₂SO δ -191.3; MS (EI, 70 eV): 261 [M], 219 [M-CH₃CO+H], 196; HRMS (ESI, *m/z*): calcd. for C₁₂H₁₂FFeNO 261.02468, found 261.02450 (1 ppm) M⁺.

N-(2-(*N*-Methyl-3-indolylmethyl)ferrocenyl)-2-pyrrolidinone (**4n**, racemic mixture). The general procedure 1 but from 1-iodo-2-(*N*-methyl-3-indolylmethyl)ferrocene (0.30 g; 0.66 mmol) gave **4n** (eluent: petroleum ether-AcOEt 50:50; R_f = 0.22) in 11% yield (30 mg) as an orange sticky oil: IR (ATR) 737, 817, 909, 1000, 1035, 1057, 1105, 1130, 1154, 1201, 1253, 1284, 1305, 1327, 1373, 1393, 1424, 1472, 1551, 1614, 1686, 2884, 3088 cm⁻¹; ¹H NMR (CDCl₃) δ 1.95-2.06 (m, 2H, CH₂CH₂-C=O), 2.33-2.46 (m, 2H, CH₂-C=O), 3.69 (s, 3H, Me), 3.80 (d, 1H, J = 16.3 Hz, CHH-indolyl), 3.83-3.87 (m, 2H, CH₂-N), 3.91 (d, 1H, J = 16.3 Hz, CHH-indolyl), 4.05 (t, 1H, J = 2.2 Hz, H4), 4.07 (s, 1H, H3), 4.22 (s, 5H, Cp), 4.49 (s, 1H, H5), 6.69 (s, 1H, H2'), 7.12 (t, 1H, J = 7.4 Hz, H5'), 7.22 (t, 1H, J = 7.2 Hz, H6'), 7.27 (d, 1H, J = 8.2 Hz, H7'), 7.60 (d, 1H, J = 8.0 Hz, H4'); ¹³C NMR (CDCl₃) δ 19.0 (CH₂, CH₂CH₂-C=O), 24.2 (CH₂-indolyl), 32.1 (CH₂, CH₂-C=O), 32.7 (CH₃, Me), 52.4 (CH₂, CH₂-N), 64.2 (CH, C4), 65.4 (CH, C5), 67.6 (CH, C3), 69.6 (5CH, Cp), 81.8 (C, C2, C-CH₂-indolyl), 94.1 (C, C1, C-N), 109.2 (CH, C7', C7-indolyl), 114.0 (C, C3', C3-indolyl), 118.8 (CH, C5', C5-indolyl), 118.9 (CH, C4', C4-indolyl), 121.5 (CH, C6', C6-indolyl), 127.1 (CH, C2', C2-indolyl), 127.7 (C, Cb-indolyl), 137.0 (C, Ca-indolyl), 175.2 (C, Me-C=O).

General procedure 2. The iodoferrrocene (1.0 mmol), CuI (0.19 g, 1.0 mmol), *t*BuOK (0.11 g, 2.0 mmol) and acetamide (65 mg, 1.1 mmol) were introduced in a degassed Schlenk tube and dissolved in DMSO (2 mL). The mixture was stirred under argon and heated at 90 °C overnight. It was then allowed to cool to room temperature before addition of water (10 mL). After extraction with AcOEt (3 x 20 mL) and drying over MgSO₄, the coupling product was purified by chromatography over silica gel (the eluent is given in the product description).

N-(2-(Methoxymethyl)ferrocenyl)acetamide (**2d**, racemic mixture). The general procedure 2 from 1-iodo-2-(methoxymethyl)ferrocene (**1d**; 0.36 g) gave **2d** (eluent: hexane-AcOEt 60:40) in 19% yield (56 mg) as an orange solid. The analyses are as reported before in the present paper.

N-(2-(Methoxycarbonyl)ferrocenyl)acetamide (**2i**, racemic mixture). The general procedure 2 from methyl 2-iodoferrocenecarboxylate (**1i**; 0.37 g) gave **2i** (eluent: hexane-AcOEt 60:40) in 4.5% yield (13 mg) as an orange solid. The analyses are as reported before in the present paper.

N-(2-(Diisopropylaminocarbonyl)ferrocenyl)acetamide (**2j**, racemic mixture). The general procedure 2 from *N,N*-diisopropyl-2-iodoferrocenecarboxamide (**1j**; 0.44 g) gave **2j** (eluent: hexane-AcOEt 60:40) in 6.5% yield (23 mg) as an orange solid. The analyses are as reported before in the present paper.

Computational Details. All electronic structure calculations were conducted using Gaussian 09 suite.^[49] Full geometry optimizations of the considered species were performed using the B3LYP hybrid functional.^[50] Before optimizing the geometry, a conformational search has been done for structurally flexible species. Vibrational frequencies were calculated to prove the nature of the stationary points and to derive thermochemical corrections for enthalpies and free energies. The LANL2DZ basis set^[51] with the effective core potential was used to describe Fe, Cu, and I, while the 6-31G(d) basis set^[52] was used to treat the rest of the atoms. The free energy of activation was calculated as the difference between the free energy of the transition-state structure and the sum of the free energies of the initial [(dmeda)Cu(pyr)] complex and iodobenzene or iodoferrrocene. We used LANL2TZ(f) basis set^[53] for Fe and Cu atoms and LANL2DZ(d,p)

basis set^[54] for I atom for the free energy calculation. Mulliken, APT and NBO atomic charges were obtained at the same level using different population analysis schemes in Gaussian 09. For generation of Hirshfeld atomic charges and various conceptual DFT (CDFT) reactivity indices Multiwfn program^[55] was used.

The polarizable continuum model (IEF-PCM)^[56] was used to account for solvation effects with a default parameters of 1,4-dioxane to emulate the reaction conditions.

CDFT is aiming for unraveling of reactivity of chemical systems.^[57] Its descriptors can be used to predict favorable reactive sites and compare reactivity of different species. In the present work the following properties were calculated:

global – frontier orbital energies (E_{HOMO} , E_{LUMO}), Mulliken electronegativity (χ), hardness (η), electrophilicity index (ω), nucleophilicity index (Nu); local – condensed Fukui function for nucleophilic (f^+), electrophilic (f^-) and radical attack (f^0); condensed local softness for nucleophilic (s^+), electrophilic (s^-) and radical attack (s^0); relative electrophilicity index (sr), condensed local electrophilicity index (ω^{loc}), condensed local nucleophilicity index (Nu^{loc}).

Their thorough definition and explanation could be found elsewhere.^[57-58]

Acknowledgements

This work was supported by the Université de Rennes 1 and CNRS. The authors would like to thank Rennes Métropole for a doctoral mobility fellowship (L. K.) and Région Bretagne for a postdoctoral fellowship grant (L. K.). We gratefully acknowledge the Fonds Européen de Développement Régional (FEDER; D8 Venture Bruker AXS diffractometer), Thermofisher (generous gift of 2,2,6,6-tetramethylpiperidine), and the Hyderabad CSIR-Indian Institute of Chemical Technology for recording the High Resolution Mass Spectra (HRMS). This research has been performed as part of the Indo-French 'Joint Laboratory for Natural Products and Synthesis towards Affordable Health'.

Keywords: Ferrocene • Amide • Copper • Coupling • Substituent effect

- [1] I. Goldberg, *Ber. Dtsch. chem. Ges.* **1906**, *39*, 1691-1692.
- [2] a) I. P. Beletskaya, A. V. Cheprakov, *Coord. Chem. Rev.* **2004**, *248*, 2337-2364; b) G. Evano, N. Blanchard, M. Toumi, *Chem. Rev.* **2008**, *108*, 3054-3131; c) F. Monnier, M. Taillefer, *Angew. Chem. Int. Ed.* **2009**, *48*, 6954-6971; d) I. P. Beletskaya, A. V. Cheprakov, *Organometallics* **2012**, *31*, 7753-7808; e) J. Bariwal, E. Van der Eycken, *Chem. Soc. Rev.* **2013**, *42*, 9283-9303; f) F. Monnier, M. Taillefer, *Top. Organomet. Chem.* **2013**, *46*, 173-204; g) C. Sambigioglio, S. P. Marsden, A. J. Blacker, P. C. McGowan, *Chem. Soc. Rev.* **2014**, *43*, 3525-3550; h) A. M. Thomas, A. Sujatha, G. Anilkumar, *Mini-Rev. Org. Chem.* **2015**, *12*, 3-23.
- [3] G. X. Yang, L. L. Chang, Q. Truong, G. A. Doherty, P. A. Magriotis, S. E. de Laszlo, B. Li, M. MacCoss, U. Kidambi, L. A. Egger, E. McCauley, G. Van Riper, R. A. Mumford, J. A. Schmidt, W. K. Hagmann, *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1497-1500.
- [4] T. Beghyn, C. Hounsou, B. P. Deprez, *Bioorg. Med. Chem. Lett.* **2007**, *17*, 789-792.
- [5] T. B. Beghyn, J. Charton, F. Leroux, G. Laconde, A. Bourin, P. Cos, L. Maes, B. Deprez, *J. Med. Chem.* **2011**, *54*, 3222-3240.
- [6] H. Bregman, N. Chakka, A. Guzman-Perez, H. Gunaydin, Y. Gu, X. Huang, V. Berry, J. Liu, Y. Teffera, L. Huang, B. Egge, E. L. Mullady, S. Schneider, P. S. Andrews, A. Mishra, J. Newcomb, R. Serafino, C. A. Strathdee, S. M. Turci, C. Wilson, E. F. DiMauro, *J. Med. Chem.* **2013**, *56*, 4320-4342.

- [7] M. J. Orwat, J. X. Qiao, K. He, A. R. Rendina, J. M. Luetgen, K. A. Rossi, B. Xin, R. M. Knabb, R. R. Wexler, P. Y. S. Lam, D. J. P. Pinto, *Bioorg. Med. Chem. Lett.* **2014**, *24*, 3341-3345.
- [8] J. L. Woodring, K. A. Bachovchin, K. G. Brady, M. F. Gallerstein, J. Erath, S. Tanghe, S. E. Leed, A. Rodriguez, K. Mensa-Wilmot, R. J. Sciotti, M. P. Pollastri, *Eur. J. Med. Chem.* **2017**, *141*, 446-459.
- [9] B.-R. Kang, A.-L. Shan, Y.-P. Li, J. Xu, S.-M. Lu, S.-Q. Zhang, *Bioorg. Med. Chem.* **2013**, *21*, 6956-6964.
- [10] a) A. Klapars, J. C. Antilla, X. Huang, S. L. Buchwald, *J. Am. Chem. Soc.* **2001**, *123*, 7727-7729; b) A. Klapars, X. Huang, S. L. Buchwald, *J. Am. Chem. Soc.* **2002**, *124*, 7421-7428.
- [11] a) E. R. Strieter, D. G. Blackmond, S. L. Buchwald, *J. Am. Chem. Soc.* **2005**, *127*, 4120-4121; b) E. R. Strieter, B. Bhayana, S. L. Buchwald, *J. Am. Chem. Soc.* **2009**, *131*, 78-88; c) J. W. Tye, Z. Weng, A. M. Johns, C. D. Incarvito, J. F. Hartwig, *J. Am. Chem. Soc.* **2008**, *130*, 9971-9983.
- [12] a) S.-L. Zhang, L. Liu, Y. Fu, Q.-X. Guo, *Organometallics* **2007**, *26*, 4546-4554; b) A. Casitas, X. Ribas, *Chem. Sci.* **2013**, *4*, 2301-2318; c) I. Güell, X. Ribas, *Eur. J. Org. Chem.* **2014**, *2014*, 3188-3195; d) X. Ribas, I. Güell, *Pure Appl. Chem.* **2014**, *86*, 345-360; e) K. K. Gurjar, R. K. Sharma, *ChemCatChem* **2017**, *9*, 862-869; f) M. Rovira, L. Jašiková, E. Andris, F. Acuña-Parés, M. Soler, I. Güell, M.-Z. Wang, L. Gómez, J. M. Luis, J. Roithová, X. Ribas, *Chem. Commun.* **2017**, *53*, 8786-8789.
- [13] M.-G. Wang, H. Yu, J. Wu, Z.-C. Shang, *Synthesis* **2013**, *45*, 1955-1964.
- [14] D. Astruc, *Eur. J. Inorg. Chem.* **2017**, *2017*, 6-29.
- [15] F. A. Larik, A. Saeed, T. A. Fattah, U. Muqadar, P. A. Channar, *Appl. Organomet. Chem.* **2017**, *31*, e3664.
- [16] a) M. Herberhold, M. Ellinger, W. Kremnitz, *J. Organomet. Chem.* **1983**, *241*, 227-240; b) B. Bildstein, M. Malaun, H. Kopacka, K.-H. Ongania, K. Wurst, *J. Organomet. Chem.* **1999**, *572*, 177-187; c) S. Özçubukçu, E. Schmitt, A. Leifert, C. Bolm, *Synthesis* **2007**, 389-392.
- [17] P. Srinivas, S. Prabhakar, F. Chevallier, E. Nassar, W. Erb, V. Dorcet, V. Jouikov, P. Radha Krishna, F. Mongin, *New J. Chem.* **2016**, *40*, 9441-9447.
- [18] L. Kadari, W. Erb, T. Roisnel, P. R. Krishna, F. Mongin, *New J. Chem.* **2020**, *44*, 15928-15941.
- [19] a) M. Tazi, W. Erb, Y. S. Halauko, O. A. Ivashkevich, V. E. Matulis, T. Roisnel, V. Dorcet, F. Mongin, *Organometallics* **2017**, *36*, 4770-4778; b) W. Erb, G. Levanen, T. Roisnel, V. Dorcet, *New J. Chem.* **2018**, *42*, 3808-3818; c) M. Tazi, M. Hedidi, W. Erb, Y. S. Halauko, O. A. Ivashkevich, V. E. Matulis, T. Roisnel, V. Dorcet, G. Bentabed-Ababsa, F. Mongin, *Organometallics* **2018**, *37*, 2207-2211; d) W. Erb, J.-P. Hurvois, T. Roisnel, V. Dorcet, *Organometallics* **2018**, *37*, 3780-3790; e) W. Erb, T. Roisnel, *Chem. Commun.* **2019**, *55*, 9132-9135; f) M. Hedidi, G. Dayaker, Y. Kitazawa, T. Yoshii, M. Kimura, W. Erb, G. Bentabed-Ababsa, F. Chevallier, M. Uchiyama, P. C. Gros, F. Mongin, *New J. Chem.* **2019**, *43*, 14898-14907; g) M. Tazi, W. Erb, T. Roisnel, V. Dorcet, F. Mongin, P. J. Low, *Org. Biomol. Chem.* **2019**, *17*, 9352-9359; h) W. Erb, T. Roisnel, V. Dorcet, *Synthesis* **2019**, *51*, 3205-3213; i) W. Erb, L. Kadari, K. Al-Mekhlafi, T. Roisnel, V. Dorcet, P. Radha Krishna, F. Mongin, *Adv. Synth. Catal.* **2020**, *362*, 832-850; j) L. Kadari, T. Roisnel, W. Erb, P. R. Krishna, F. Mongin, *Synthesis* **2020**, *52*, 3153-3161.
- [20] G. Dayaker, A. Sreeshailam, F. Chevallier, T. Roisnel, P. Radha Krishna, F. Mongin, *Chem. Commun.* **2010**, *46*, 2862-2864.
- [21] C. Metallinos, J. Zaifman, L. Dodge, *Org. Lett.* **2008**, *10*, 3527-3530.
- [22] a) M. Rovira, M. Soler, I. Güell, M.-Z. Wang, L. Gómez, X. Ribas, *J. Org. Chem.* **2016**, *81*, 7315-7325; b) A. Casitas, M. Canta, M. Solà, M. Costas, X. Ribas, *J. Am. Chem. Soc.* **2011**, *133*, 19386-19392.
- [23] Y. Garcia, F. Schoenebeck, C. Y. Legault, C. A. Merlic, K. N. Houk, *J. Am. Chem. Soc.* **2009**, *131*, 6632-6639.
- [24] C. Y. Legault, Y. Garcia, C. A. Merlic, K. N. Houk, *J. Am. Chem. Soc.* **2007**, *129*, 12664-12665.
- [25] a) R. Rossi, F. Bellina, M. Lessi, *Adv. Synth. Catal.* **2012**, *354*, 1181-1255; b) J. Almond-Thynne, D. C. Blakemore, D. C. Pryde, A. C. Spivey, *Chem. Sci.* **2017**, *8*, 40-62.
- [26] S. T. Handy, Y. Zhang, *Chem. Commun.* **2006**, *42*, 299-301.
- [27] I. J. S. Fairlamb, C. T. O'Brien, Z. Lin, K. C. Lam, *Org. Biomol. Chem.* **2006**, *4*, 1213-1216.
- [28] W. F. Bailey, E. A. Cioffi, K. B. Wiberg, *J. Org. Chem.* **1981**, *46*, 4219-4225.
- [29] S. Zhang, Y. Ding, *Organometallics* **2011**, *30*, 633-641.
- [30] M. S. Inkpen, S. Du, M. Hildebrand, A. J. P. White, N. M. Harrison, T. Albrecht, N. J. Long, *Organometallics* **2015**, *34*, 5461-5469.
- [31] a) I. Bennacef, C. A. Salinas, T. A. Bonasera, R. N. Gunn, H. Audrain, S. Jakobsen, N. Nabulsi, D. Weinzimmer, R. E. Carson, Y. Huang, I. Holmes, F. Micheli, C. Heidbreder, G. Gentile, T. Rossi, M. Laruelle, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5056-5059; b) S. Terentjeva, D. Muceniece, V. Lūsis, *J. Chem. Res.* **2015**, *39*, 701-705.
- [32] F. Yamada, M. Tamura, M. Somei, *Heterocycles* **1998**, *49*, 451-457.
- [33] T. Cohen, I. Cristea, *J. Org. Chem.* **1975**, *40*, 3649-3651.
- [34] S. R. Flanagan, D. C. Harrowven, M. Bradley, *Tetrahedron Lett.* **2003**, *44*, 1795-1798.
- [35] B. Speetzen, S. R. Kass, *J. Phys. Chem. A* **2019**, *123*, 6016-6021.
- [36] H. E. Gottlieb, V. Kotlyar, A. Nudelman, *J. Org. Chem.* **1997**, *62*, 7512-7515.
- [37] M. S. Inkpen, S. Du, M. Driver, T. Albrecht, N. J. Long, *Dalton Trans.* **2013**, *42*, 2813-2816.
- [38] G. M. Sheldrick, *Acta Crystallogr., Sect. A* **2015**, *71*, 3-8.
- [39] G. M. Sheldrick, *Acta Crystallogr., Sect. C* **2015**, *71*, 3-8.
- [40] L. J. Farrugia, *J. Appl. Crystallogr.* **1997**, *30*, 565.
- [41] M. Tsukazaki, M. Tinkl, A. Roglans, B. J. Chapell, N. J. Taylor, V. Snieckus, *J. Am. Chem. Soc.* **1996**, *118*, 685-686.
- [42] A. Zirakzadeh, R. Schuecker, W. Weissensteiner, *Tetrahedron: Asymmetry* **2010**, *21*, 1494-1502.
- [43] T. Pickett, E., F. Roca, X., C. Richards, J., *J. Org. Chem.* **2003**, *68*, 2592-2599.
- [44] a) A. Patti, D. Lambusta, M. Piattelli, G. Nicolosi, *Tetrahedron: Asymmetry* **1998**, *9*, 3073-3080; b) G. Dayaker, A. Sreeshailam, D. V. Ramana, F. Chevallier, T. Roisnel, S. Komagawa, R. Takita, M. Uchiyama, P. R. Krishna, F. Mongin, *Tetrahedron* **2014**, *70*, 2102-2117.
- [45] S. Pedotti, A. Patti, *Tetrahedron* **2012**, *68*, 3300-3305.
- [46] H. Lehner, K. Schlögl, *Monatsh. Chem.* **1970**, *101*, 895-911.
- [47] a) O. Riant, O. Samuel, T. Flessner, S. Taudien, H. B. Kagan, *J. Org. Chem.* **1997**, *62*, 6733-6745; b) G. Forcher, A. Silvanus, P. de Fremont, B. Jacques, M. S. M. Pearson-Long, F. Boeda, P. Bertus, *J. Organomet. Chem.* **2015**, *797*, 1-7.
- [48] G. Pavlović, L. Barisic, V. Rapic, I. Leban, *Acta Crystallographica, Section E: Structure Reports Online* **2002**, *58*, m13-m15.
- [49] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. Montgomery, J. A., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, Gaussian 09, Revision A.02, Gaussian Inc., Wallingford, CT, 2009.
- [50] a) A. D. Becke, *J. Chem. Phys.* **1993**, *98*, 5648-5652; b) C. Lee, W. Yang, R. G. Parr, *Phys. Rev. B* **1988**, *37*, 785-789.
- [51] P. J. Hay, W. R. Wadt, *J. Chem. Phys.* **1985**, *82*, 299-310.
- [52] P. C. Hariharan, J. A. Pople, *Theor. Chim. Acta* **1973**, *28*, 213-222.

- [53] a) L. E. Roy, P. J. Hay, R. L. Martin, *J. Chem. Theory Comput.* **2008**, *4*, 1029-1031; b) A. W. Ehlers, M. Böhme, S. Dapprich, A. Gobbi, A. Höllwarth, V. Jonas, K. F. Köhler, R. Stegmann, A. Veldkamp, G. Frenking, *Chem. Phys. Lett.* **1993**, *208*, 111-114.
- [54] a) W. R. Wadt, P. J. Hay, *J. Chem. Phys.* **1985**, *82*, 284-298; b) C. E. Check, T. O. Faust, J. M. Bailey, B. J. Wright, T. M. Gilbert, L. S. Sunderlin, *J. Phys. Chem. A* **2001**, *105*, 8111-8116.
- [55] T. Lu, F. Chen, *J. Comput. Chem.* **2012**, *33*, 580-592.
- [56] E. Cancès, B. Mennucci, J. Tomasi, *J. Chem. Phys.* **1997**, *107*, 3032-3041.
- [57] R. Parr, W. Yang, *Density Functional Theory of Atoms and Molecules*; Oxford University Press: New York, **1989**.
- [58] a) R. K. Roy, S. Krishnamurti, P. Geerlings, S. Pal, *J. Phys. Chem. A* **1998**, *102*, 3746-3755; b) W. Yang, R. G. Parr, *Proc. Natl. Acad. Sci. U. S. A.* **1985**, *82*, 6723-6726; c) P. Geerlings, F. De Proft, *Phys. Chem. Chem. Phys.* **2008**, *10*, 3028-3042.

